<SEC-DOCUMENT>0001171843-24-002021.txt : 20240415
<SEC-HEADER>0001171843-24-002021.hdr.sgml : 20240415
<ACCEPTANCE-DATETIME>20240415161005
ACCESSION NUMBER:		0001171843-24-002021
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20240415
FILED AS OF DATE:		20240415
DATE AS OF CHANGE:		20240415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		24844748

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_041524.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B></B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>Date of report: April 15, 2024 </B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>Commission File Number: 001-38844</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 24pt; text-align: center"><B>GENFIT S.A. </B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>(Translation of registrant&#8217;s name into English) </B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>Parc Eurasant&eacute;</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>885, avenue Eug&egrave;ne Avin&eacute;e</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>59120 Loos, France</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&#9746; Form 20-F &#9; &#8239;&#8239;&#8239;&#8239;&#8239;&#9744; Form 40-F</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B></B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>Explanatory Note</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>General Meeting</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Genfit S.A. (the &#8220;Company&#8221;) will hold its Combined Shareholders&#8217; Meeting (the
&#8220;Meeting&#8221;) on May 22, 2024 beginning at 10 a.m. CEST at the Facult&eacute; de Pharmacie de Lille located at Parc Eurasant&eacute;,
3 rue du Professeur Laguesse in Lille (59000), France.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Additional information regarding the Meeting is available to shareholders
on the Company&#8217;s website, in the Investors &amp; Media section (https://ir.genfit.com/financial-information/shareholders-meeting).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The following documents regarding the Company&#8217;s Meeting, which are
attached as exhibits hereto, are incorporated by reference herein.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXHIBIT LIST</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 6%">
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: black 1pt solid"><B>Exhibit</B></P></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 90%">
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; border-bottom: black 1pt solid"><B>Description</B></P></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="exh_991.htm">99.1</A></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="exh_991.htm">Press Release dated April 15, 2024.</A></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><A HREF="exh_992.htm">99.2</A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="exh_992.htm">Notice of the combined shareholder meeting</A></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SIGNATURES</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>GENFIT S.A.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 52%"><FONT STYLE="font-size: 10pt">Date: April 15, 2024</FONT></TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; width: 44%"><FONT STYLE="font-size: 10pt">/s/ Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Name: Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="text-align: right; font-size: 10pt; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0pt 0; text-align: right; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><B><IMG SRC="hdr.jpg" ALT=""></B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt; text-align: center; color: #005478"><FONT STYLE="font-size: 12pt"><B>GENFIT Annual
Combined General Meeting of May 22, 2024 &#8212;</B></FONT></P>

<P STYLE="margin: 0pt 0.1pt 0pt 0pt; font-size: 10pt; text-align: center; color: #005478"><FONT STYLE="font-size: 12pt"><B>Availability
of Preparatory Documents</B></FONT></P>

<P STYLE="margin: 0pt 0 0pt -20pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt; text-align: justify; color: #005278"><B>Lille (France); Cambridge (Massachusetts, United
States); Zurich (Switzerland); April 15, 2024 <FONT STYLE="color: Black">- GENFIT (Nasdaq and Euronext: GNFT)</FONT></B><FONT STYLE="color: Black">,
a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today
announced that it published in the April 15, 2024 French legal announcements bulletin n&deg;46 (<I>Bulletin des Annonces L&eacute;gales
Obligatoires</I>) its convening notice that the Combined Shareholders Meeting will be held on May 22, 2024, at 10:00am (CET), at the
Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasant&eacute;, 3 rue du Professeur Laguesse, 59000 Lille, France.</FONT></P>

<P STYLE="margin: 0pt 0 0pt -20pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify"><FONT STYLE="color: Black">All documentation regarding this
Shareholders&#8217; Meeting will be available to shareholders in accordance with existing regulations, and will be available on the Company&#8217;s
website, in the Financials section under the Shareholders Meeting tab (https://ir.genfit.com/financial- information/shareholders-meeting).</FONT></P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 5.75pt 0pt 0pt; font-size: 10pt; text-align: justify">For this 2024 Combined General Meeting, the Company will
allow shareholders to send their voting instructions via Internet through the VOTACCESS platform. A tutorial to familiarize shareholders
with this online voting platform will be made available in the same section of the website as soon as the platform is opened.</P>

<P STYLE="margin: 0pt 0 0pt -20pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt -20pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt; text-align: justify; color: #005478"><B>ABOUT GENFIT</B></P>

<P STYLE="margin: 0pt 0 0pt -20pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">GENFIT is a late-stage biopharmaceutical company dedicated
to improving the lives of patients with rare and life-threatening liver diseases characterized by high unmet medical needs. GENFIT is
a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades.
Today, GENFIT has a growing and diversified pipeline with programs at various development stages. The Company&#8217;s area of focus is
Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise consists of five assets in development: VS-01, NTZ, SRT-015, CLM-022 and VS-02-HE.
These are all based on differentiated mechanisms of action leveraging complementary pathways. Other assets target other life-threatening
disease indications such as cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD)/Organic Acidemias (OA). GENFIT&#8217;s track record
in bringing early-stage assets with high potential to late development and pre- commercialization stages is highlighted in the successful
52-week Phase 3 ELATIVE<FONT STYLE="font-size: 10pt">&reg;</FONT> trial evaluating elafibranor in PBC. Beyond therapeutics, GENFIT&#8217;s
pipeline also includes a diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH) previously known as nonalcoholic
steatohepatitis (NASH) and ammonia. GENFIT has facilities in Lille and Paris (France),</P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><IMG SRC="footer.jpg" ALT="" STYLE="height: 26px; width: 626px"></P>

<P STYLE="margin: 0pt 5.7pt 0pt 0pt; font-size: 10pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center"><IMG SRC="hdr.jpg" ALT=""></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"></P>

<P STYLE="margin: 0pt 6pt 0pt 0pt; font-size: 10pt; text-align: justify">Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly
traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext&#8217;s regulated market in Paris (Nasdaq and
Euronext: GNFT). In 2021, IPSEN became one of GENFIT&#8217;s largest shareholders and holds 8% of the company&#8217;s share capital. For
more information, visit www.genfit.com</P>

<P STYLE="margin: 0pt 0 0pt -20pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt; color: #005478"><B>FORWARD LOOKING STATEMENTS</B></P>

<P STYLE="margin: 0pt 0 0pt -20pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 5.65pt 0pt 0pt; font-size: 10pt; text-align: justify">This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including &#8220;believe&#8221;,
&#8220;potential,&#8221; &#8220;expect&#8221;, &#8220;target&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;if&#8221; and similar
expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current
expectations and reasonable assumptions of the Company&#8217;s management, these forward- looking statements are subject to numerous known
and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected
by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research
and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned
clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic
candidates, potential commercial success of elafibranor if approved, exchange rate fluctuations, our continued ability to raise capital
to fund our development, as well as those risks and uncertainties discussed or identified in the Company&#8217;s public filings with the
AMF, including those listed in Chapter 2 &#8220;Main Risks and Uncertainties&#8221; of the Company&#8217;s 2023 Universal Registration
Document (n&deg; D.24-0246) filed with the AMF on April 5, 2024, which is available on the Company&#8217;s website (www.genfit.com) and
on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;)
including the Company&#8217;s 2023 Annual Report on Form 20-F filed with the SEC on April 5, 2024. In addition, even if the Company&#8217;s
results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with
such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements
speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any
obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or
otherwise.</P>

<P STYLE="margin: 0pt 0 0pt -20pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt; color: #005478"><B>CONTACT</B></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt; color: #005478">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt; text-align: justify"><B>GENFIT</B> | Investors</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Tel: +33 3 2016 4000 |</FONT> investors@genfit.com</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"></P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"><B>PRESS RELATIONS</B> | Media</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt">Stephanie Boyer &#8211; Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><IMG SRC="footer.jpg" ALT="" STYLE="height: 26px; width: 626px">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt"></P>

<P STYLE="text-align: right; margin: 0pt 0 0pt 0pt; font-size: 10pt">2</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt 0 0pt 0pt; font-size: 10pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exh_992.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">APRIL 15, 2024 FRENCH OFFICIAL LEGAL ANNOUNCEMENTS PUBLICATION &laquo;BALO&raquo;
BULLETIN N&deg;46</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><I>This document has been translated in English for information only. In
the event of any differences between the French text and the English text, the French language version shall supersede</I>.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>SHAREHOLDERS' MEETING</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>GENFIT</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">French public limited company (<I>Soci&eacute;t&eacute; Anonyme</I>) with
a Board of Directors<BR>
With share capital of 12,465,245.75 euros<BR>
Registered Office: 885 avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos, France<BR>
424 341 907 R.C.S. Lille M&eacute;tropole</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>Notice of meeting serving as convening notice</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Ladies and Gentlemen, the shareholders of the company GENFIT S.A. (the &ldquo;<B>Company</B>&rdquo;)
are convened to a Combined Shareholders&rsquo; General Meeting (ordinary and extraordinary) (the &ldquo;<B>Shareholders&rsquo; Meeting</B>&rdquo;)
in the offices of the Facult&eacute; de Pharmacie de Lille located Parc Eurasant&eacute;, 3 rue du Professeur Laguesse in Lille (59000),
France on Wednesday, May 22, 2024 at 10:00 a.m. (Paris time), to deliberate on the agenda provided below.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">In the event where the Shareholders&rsquo; Meeting could not deliberate
due to the required quorum for extraordinary shareholders&rsquo; meeting held on first convening not being reached on first notice, the
Shareholders&rsquo; Meeting will be reconvened to deliberate on the same agenda, on Monday, June 24, 2024 at 2:30 p.m. (Paris time).</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>Agenda</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>Ordinary Shareholders&rsquo; Meeting</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Presentation of the Board of Director&rsquo;s management report on the Company&rsquo;s activity and on
the financial statements for the year ended on December 31, 2023, and of the Statutory auditors&rsquo; general report on the financial
statements for the year ended on December 31, 2023;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Presentation of the Group&rsquo;s management report by the Board of Directors and reading of the Statutory
auditors&rsquo; general report on the consolidated financial statements for the year ended on December 31, 2023;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Presentation the Board of Directors&rsquo; corporate governance report;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Approval of the annual financial statements for the year ended on December 31, 2023 (<B>Resolution n&deg;</B>1);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Approval of the consolidated financial statements for the year ended on December 31, 2023 (<B>Resolution
n&deg;2</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Allocation of the results for the year ended on December 31, 2023 (<B>Resolution n&deg;3</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Statutory Auditors&rsquo; special report on the regulated agreements (<B>Resolution n&deg;4</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Reading of the Board of Directors special report on the options to subscribe or purchase Company&rsquo;s
shares (<I>options de souscription ou d&rsquo;achat d&rsquo;actions</I>) in accordance with Article L.225-184 of the French <I>Code de
commerce</I>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Reading of the Board of Directors&rsquo; special report on the granting of free shares (<I>actions gratuites</I>)
in accordance with Article L.225-197-4 of the French <I>Code de commerce</I>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Reading of the table summarizing the delegations of authority and powers granted by the shareholders&rsquo;
meeting to the Board of Directors in respect of capital increases, in accordance with Articles L.225-129-1, L.225-129-5, L.225-129-6 et
L.22-10-49 <I>et seq.</I> of the French <I>Code de commerce</I>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Reading of the Board of Directors&rsquo; supplementary report on the use of delegations of powers granted
by the shareholders meeting, in accordance with Article R.225-116 of the French <I>Code de commerce;</I></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Reappointment of Ernst &amp; Young et Autres as Statutory Auditors (<B>Resolution n&deg;5</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Reappointment of Auditex as alternate Statutory Auditors (provided that resolution n&deg;28 is not adopted)
(<B>Resolution n&deg;6</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Reappointment of Grant Thornton as Statutory Auditors (<B>Resolution n&deg;7</B>);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Reappointment of Institut Gest Expert Comptable &ndash; IGEC as alternate Statutory Auditors (provided
that resolution n&deg;28 is not adopted) (<B>Resolution n&deg;8</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Approval of the information relating to the components of overall compensation paid during the 2023 financial
year, or allocated for the same financial year, to all of the Company&rsquo;s corporate officers (<B>Resolution n&deg;9</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Approval of the components of overall compensation paid during the 2023 financial year, or allocated for
the same financial year to the Chairman of the Board of Directors of the Company (<B>Resolution&nbsp;n&deg;10</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Approval of the components of overall compensation paid during the 2023 financial year, or allocated for
the same financial year to the Chief Executive Officer of the Company (<B>Resolution n&deg;11</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Approval of the compensation policy for the financial year 2024 applicable to all of the Company&rsquo;s
corporate officers (<B>Resolution n&deg;12</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Approval of the compensation policy for the financial year 2024 applicable to the Chairman of the Board
of Directors of the Company (<B>Resolution n&deg;13</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Approval of the compensation policy for the financial year 2024 applicable to the Chief Executive Officer
of the Company (<B>Resolution n&deg;14</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Approval of the compensation policy for the financial year 2024 applicable to the Directors of the Company
(<B>Resolution n&deg;15</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Authorisation for the Company&rsquo;s repurchase of its own shares (<B>Resolution n&deg;16</B>);</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Extraordinary Shareholders&rsquo; Meeting</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Delegation of authority granted to the Board of Directors to issue ordinary shares of the Company and/or
securities giving access to the share capital of the Company, without Shareholders&rsquo; preferential subscription rights, within the
framework of an offering other than those referred to in paragraph 1&deg; of Article L.411-2 of the French C<I>ode mon&eacute;taire et
financier </I>(<B>Resolution n&deg;17</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Delegation of authority granted to the Board of Directors to issue, without shareholders&rsquo; preferential
subscription rights, ordinary shares of the Company and/or securities giving access to the share capital of the Company, within the framework
of an offering as referred to in paragraph 1&deg; of Article L.411- of the <I>French Code mon&eacute;taire et financier</I>, known as
&ldquo;private placement&rdquo; (<B>Resolution n&deg;18</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Determination of the issue price, in accordance with resolutions n&deg;17 and 18 above mentioned, of the
ordinary shares and/or of the securities giving access to the share capital of the Company, in the event of a renunciation of shareholders&rsquo;
preferential subscription rights (<B>Resolution n&deg;19</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Delegation of authority granted to the board of Directors to issue ordinary shares and/or securities giving
access to the share capital of the Company without preferential subscription rights and for the benefit of a category of persons (<B>Resolution
n&deg;20</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Delegation of authority granted to the Board of Directors to issue ordinary shares and/or securities giving
access to the share capital of the company, as compensation for contributions in kind comprised of equity securities or securities giving
access to the share capital (<B>Resolution n&deg;21</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Delegation of power granted to the Board of Directors to cancel all or part of the shares held by the
Company under the share buyback authorisation (<B>Resolution n&deg;22</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Authorisation granted to the Board of Directors to allocate options to subscribe and/or purchase shares
(<B>Resolution n&deg;23</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Authorisation granted to the Board of Directors to allocate free, existing or new, shares (<B>Resolution
n&deg;24</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Delegation of authority granted to the Board of Directors for the purpose of issuing ordinary shares and/or
securities giving access to the share capital of the Company for the benefit of the members of a company&rsquo;s saving plan (<B>Resolution
n&deg;25</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Amendment of Article 4.2 of the Company&rsquo;s articles of association to complete the description of
its <I>raison d&rsquo;&ecirc;tre</I> (<B>Resolution n&deg;26</B>);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Amendment of Article 18 II of the Company&rsquo;s articles of association to facilitate Board Meetings
(<B>Resolution n&deg;27</B>)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Amendment of Article 26 of the Company&rsquo;s articles of association to remove the statutory obligation
to appoint one or more alternate Statutory Auditors (<B>Resolution n&deg;28</B>).</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>Ordinary Shareholders&rsquo; Meeting</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 14.2pt">-</TD><TD STYLE="text-align: justify">Powers to complete formalities (<B>Resolution n&deg; 29</B>).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>PROJET DE R&Eacute;SOLUTIONS<BR></U></B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B><U></U>Assembl&eacute;e G&eacute;n&eacute;rale Ordinaire</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>First Resolution &ndash; Approval of the annual financial statements for the year ended on
December 31, 2023</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for ordinary shareholders&lsquo; meetings, having reviewed the Board of Directors&rsquo; report on the Company&rsquo;s annual
financial statements and having reviewed he Statutory Auditors&rsquo; report for the year ended on December 31, 2023, approves the financial
statements, as they are presented to them, prepared according to French standards and in compliance with the French <I>Code de commerce</I>,
which show a net loss of 20,186,528 euros.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting also approves the operations reflected
in these annual financial statements or summarized in these reports.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Under Articles 223 <I>quarter</I> and 223 <I>quinquies</I> of the French
<I>Code g&eacute;n&eacute;ral des imp&ocirc;ts</I>, the Shareholders&rsquo; Meeting notes that there are no expenditures or charges deductible
from the Company&rsquo;s taxable income as referred to in Article 39.4 of the French <I>Code general des imp&ocirc;ts</I>.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">After having deliberated, the Shareholders&rsquo; Meeting gives to the
member of the Board of Directors and the Statutory Auditors, full and unconditional discharge from their duties for the year ended December
31, 2023.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Second Resolution &ndash; Approval of the consolidated financial statements
for the year ended on December 31, 2023</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for ordinary shareholders&rsquo; meetings, having reviewed the Board of Directors&rsquo; report and the Statutory Auditors'
report for the year ended on December 31, 2023, approves, as they are presented to them, the consolidatedfinancial statements prepared
according to the international financial reporting standards and the IFRS accounting standards, which show a net loss of 28,894,415 euros
as well as the operations reflected in these statements or summarized in these reports.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">After having deliberated, the Shareholders&rsquo; Meeting gives to the
members of the Board of Directors and to the Statutory Auditors, full and unconditional discharge from their duties for the year ended
December 31, 2023.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>Third Resolution &ndash; Allocation of the results for the year ended on December 31, 2023</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for ordinary shareholders&rsquo; meetings, approves the proposal of the Board of Directors regarding the allocation of the
results for the financial year 2023 and thus decides to allocate the net income for the year ended on December 31, 2023 as follows:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">ORIGIN</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">Net loss for the year ended on December 31, 2023</TD>
  <TD STYLE="width: 50%">20,186,528 euros</TD></TR>
</TABLE>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">ALLOCATION</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Allocation to the item &quot;Retained earnings&quot;,</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">For a total of</TD>
  <TD STYLE="width: 50%">20,186,528 euros</TD></TR>
</TABLE>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">This thus brings the retained earnings from 349,980,598 euros to 370,167,126 euros.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting acknowledges, in accordance with Article
243 bis of the French <I>Code g&eacute;n&eacute;ral des imp&ocirc;ts</I>, that so far there has been no distribution of dividends during
the previous three financial years.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Fourth Resolution &ndash; Statutory Auditors&rsquo; special report on
regulated agreements</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">After having deliberated, the Shareholders&rsquo; Meeting, deciding under
the quorum and majority requirements for ordinary shareholders&rsquo; meetings and, having reviewed the Statutory Auditors&rsquo; report
prepared pursuant to the provisions of Articles L.225-38 and L.225-40 of the French <I>Code de commerce </I>takes note of such report
and approves the new regulated agreement referred to therein in accordance with Article L.225-38 of the French <I>Code de commerce</I>.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Fifth Resolution &ndash; Reappointment of Ernst &amp; Young et Autres
as Statutory Auditors</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Having noted the expiry of Ernst &amp; Young et Autres&rsquo; mandate as
Statutory Auditors, the Shareholders&rsquo; Meeting, deciding under the quorum and majority requirements for ordinary shareholders&rsquo;
meeting, reappoints Ernst &amp; Young et Autres, 1-2 place des Saisons &ndash; 92400 Courbevoie &ndash; Paris La D&eacute;fense 1, as
Statutory Auditors, for a period of six (6) years, that is until the Shareholders&rsquo; Meeting which will approve the financial statements
for the year ending December 31, 2029.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Sixth Resolution &ndash; Reappointment of Auditex as alternate Statutory
Auditors (provided that resolution n&deg;28 is not adopted)</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Having noted the expiry of Auditex&rsquo;s mandate as alternate Statutory
Auditors, the Shareholders&rsquo; Meeting, deciding under the quorum and majority requirements for ordinary shareholders&rsquo; meeting,
reappoints Auditex, 1-2 place des Saisons &ndash; 92400 Courbevoie &ndash; Paris La D&eacute;fense 1, as alternate Statutory Auditors,
for a period of six (6) years, that is until the Shareholders&rsquo; Meeting which will approve the financial statements for the year
ending December 31, 2029.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Seventh Resolution &ndash; Reappointment of Grant Thornton as Statutory
Auditors</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Having noted the expiry of Grant Thorton&rsquo;s mandate as alternate Statutory
Auditors, the Shareholders&rsquo; Meeting, deciding under the quorum and majority requirements for ordinary shareholders&rsquo; meeting,
reappoints Grant Thorton, 29, Rue du Pont &ndash; 92200 Neuilly sur Seine, as Statutory Auditors, for a period of six (6) years, that
is until the Shareholders&rsquo; Meeting which will approve the financial statements for the year ending December 31, 2029.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Eight Resolution &ndash; Reappointment of Institut Gest Expert Comptable
- IGEC as alternate Statutory Auditors (provided that resolution n&deg;28 is not adopted)</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">Having noted the expiry of Institut Gest Expert Comptable &ndash; IGEC&rsquo;s
mandate as alternate Statutory Auditors, the Shareholders&rsquo; Meeting, deciding under the quorum and majority requirements for ordinary
shareholders&rsquo; meeting, reappoints Institut Gest Expert Comptable &ndash; IGEC, 22, Rue Garnier &ndash; 92200 Neuilly sur Seine,
as alternate Statutory Auditors, for a period of six (6) years, that is until the Shareholders&rsquo; Meeting which will approve the financial
statements for the year ending December 31, 2029.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Ninth Resolution &ndash; Approval of the information relating to the
components of overall compensation paid during the 2023 financial year, or allocated for the same financial year, to all of the Company&rsquo;s
corporate officers</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for ordinary shareholders&rsquo;&nbsp;meetings, after having reviewed the information contained in section 3.2 of the Company's
2023 Universal Registration Document, approves, in accordance with Article L.22-10-34, I of the French <I>Code du commerce</I>, the information
mentioned in I of Article L.22-10-9 of the French <I>code de commerce</I>.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Tenth Resolution &ndash; Approval of the overall compensation paid during
the 2023 financial year, or allocated for the same financial year to the Chairman of the Board of Directors of the Company</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for ordinary shareholders&rsquo;&nbsp;meetings, after having reviewed the information contained in section 3.2 of the Company's
2023 Universal Registration Document, approves, in accordance with Article L.22-10-34, II of the French <I>Code du commerce</I>, the compensation
paid during the 2023 financial year or allocated for the same financial year to the Chairman of the Board of Directors of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Eleventh Resolution &ndash; Approval of the components of overall compensation
paid during the 2023 financial year, or allocated for the same financial year, to the Chief Executive Officer of the Company </B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for ordinary shareholders&rsquo;&nbsp;meetings, after having reviewed the information contained in section 3.2 of the Company's
2023 Universal Registration Document, approves, in accordance with Article L.22-10-34, II of the French <I>Code du commerce</I>, the compensation
paid during the 2023 financial year or allocated for the same financial year to the Chief Executive Officer.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Twelfth Resolution &ndash; Approval of the compensation policy for the
financial year 2024 applicable to all of the Company's corporate officers</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for ordinary shareholders&rsquo; meetings, in accordance with Article L.22-10-8 of the French <I>Code de commerce</I>, after
having reviewed the information presented in Section 3.2 of the Company&rsquo;s 2023 Universal Registration Document, approves, pursuant
to Article L.22-10-8, II of the French <I>Code de commerce,</I> the compensation policy for corporate officers for the financial year
2024 applicable to all of the corporate officers of the Company<B>.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Thirteenth Resolution &ndash; Approval of the compensation policy for
the financial year 2024 applicable to the Chairman of the Board of Directors of the Company</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for ordinary shareholders&rsquo; meetings, in accordance with Article L.22-10-8 of the French <I>Code de commerce</I>, after
having reviewed the information presented in Section 3.2 of the Company&rsquo;s 2023 Universal Registration Document, approves, pursuant
to Article L.22-10-8, II of the French <I>Code de commerce,</I> the compensation policy for corporate officers for the financial year
2024 applicable to the Chairman of the Board of Directors of the Company<B>.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Fourteenth Resolution &ndash; Approval of the compensation policy for
the financial year 2024 o the Chief Executive Officer of the Company </B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for ordinary shareholders&rsquo; meetings, in accordance with Article L.22-10-8 of the French <I>Code de commerce</I>, after
having reviewed the information presented in Section 3.2 of the Company&rsquo;s 2023 Universal Registration Document, approves, pursuant
to Article L.22-10-8, II of the French <I>Code de commerce,</I> the compensation policy for corporate officers for the financial year
2024 applicable to the Chief Executive Officer of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Fifteen Resolution &ndash; Approval of the compensation policy for the
financial year 2024 applicable to the Directors of the Company</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for ordinary shareholders&rsquo; meetings, after having reviewed the information presented in Section 3.2 of the Company&rsquo;s
2023 Universal Registration Document, approves, pursuant to Article L.22-10-8, II of the French <I>Code de commerce,</I> the compensation
policy for corporate officers for the financial year 2024 applicable to the Directors of the Company.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Sixteenth Resolution &ndash; Authorisation for the Company&rsquo;s repurchase
of its own shares</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for ordinary shareholders&rsquo; meetings, after having deliberated and reviewed the Board of Directors&rsquo; report, authorizes
the Board of Directors, along with the power to sub-delegate, pursuant to the conditions set forth in Articles L.22-10-62 <I>et seq</I>.
of the French <I>Code de commerce</I>, to repurchase Company&rsquo;s own shares through the implementation of a share buy-back program.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting decides that:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: center; width: 3%">-</TD>
  <TD STYLE="width: 97%">the maximum purchase price (excluding expenses) per share is set at &euro;25.00, it being specified that, in accordance with the provisions
of the European Regulation n&deg;2016/1052 of March 8, 2016, the Company may not buy shares at a higher price than the highest of the
following value: the last quoted price resulting from the execution of a transaction in which the Company was not involved or the highest
outstanding independent bid on the trading platform where the purchase will have been made ; and</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: center">-</TD>
  <TD>the maximum amount of funds allocated to the implementation of this share buy-back program may not exceed &euro;10,000,000.</TD></TR>
</TABLE>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Shareholders&rsquo; Meeting grants to the Board of Directors, along
with the power to sub-delegate within the conditions set by Article L.22-10-62 French <I>Code de commerce</I>, in the event of a change
in the par value of the share, in the event of a capital increase through incorporation of reserves, in the event of an issue of consideration
free shares, stock split or reverse stock split, distribution of reserves or of any other assets, in the event of a redemption of capital
or of any other transaction affecting equity, to adjust the maximum purchase price in such so as to take account of the impact of such
transactions on the share value.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting decides that the Company may purchase a
number of shares such that:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&mdash; the maximum number of shares that may be acquired pursuant to this
authorization may not exceed ten percent (10%) of the total number of shares comprising the Company&rsquo;s share capital and five percent
(5%) of the total number of shares comprising the Company&rsquo;s share capital for the acquisitions made to retain shares and to subsequently
use them as payment or in an exchange in the context of a merger, demerger or contribution transaction; it being specified that (i) these
limits apply to an amount of the Company&rsquo;s share capital that will be adjusted, if necessary, to take into account those transactions
that will affect the share capital subsequent to this Shareholders&rsquo; Meeting, and (ii) when the shares are bought back to promote
liquidity under the conditions set out by the General Regulations of the French <I>Autorit&eacute; des march&eacute;s financiers</I>,
the number of shares taken into account to calculate the above mentioned 10% limit corresponds to the number of shares purchased, minus
the number of shares re-sold during the authorization period; and</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&mdash; the acquisitions carried out by the Company must not result in
the Company holding, at any moment whatsoever, directly or indirectly, more than ten percents (10%) of its share capital.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This authorization is intended to allow the Company to pursue the following
objectives, in compliance with applicable laws and regulations:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 0.25in">a)</TD>
  <TD>to retain the Company&rsquo;s shares that will have been purchased and to use them in exchange or in payment within the context of potential
external growth transactions (mergers, demeregers, acquisitions), in accordance with securities laws and regulations;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: left">b)</TD>
  <TD>to deliver shares upon the exercise of rights attached to securities giving access to the share capital of the Company;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: left">c)</TD>
  <TD>to allocate shares to employees or corporate officers of the Company or its subsidiaries in accordance with the terms and conditions set
forth by law, in particular with respect to the allocation of free shares, the participation in the profits resulting from the expansion
of the business, the stock option plans or through a company&rsquo;s savings plan;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: left">d)</TD>
  <TD>to ensure liquidity and to promote the secondary market for the Company&rsquo;s securities, which would be accomplished by an investment
services provider acting under a liquidity contract in compliance with the ethics charter approved by the French Autorit&eacute; des march&eacute;s
financiers;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: left">e)</TD>
  <TD>to cancel all or part of the repurchased securities, provided the twenty-second resolution below is adopted; and</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: left">f)</TD>
  <TD>to accomplish all other authorized goals or goals that could become authorized by law or recognized or that would be recognized as a market
practice by the French Autorit&eacute; des march&eacute;s financiers, in which case the Company would inform its shareholders by way of
a press release.</TD></TR>
</TABLE>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Shareholders&rsquo; Meeting decides that these purchase, sale, exchange
or transfer transactions may be carried out by any means, that is, either on the regulated market, on a multilateral trading facility,
through a systematic internalizer or through an over-the-counter transaction, such as an acquisition or block trades, or by resorting
to financial instruments, in particular financial derivatives instruments negotiated on a regulated market, on a multilateral trading
facility, through a systematic internalizer or through a private transaction or by resorting to warrants, in compliance with the conditions
set forth by the legislative and regulatory provisions that are applicable on the date of the considered transactions and during the periods
set by the Company&rsquo;s Board of Directors or by the person to whom the Board of Directors delegated its authority. The maximum portion
of the share capital acquired or transferred in the form of blocks trades can be the total amount of the share buyback program.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Moreover, the Shareholders&rsquo; Meeting grants full powers to the Board
of Directors, along with the power to sub-delegate pursuant to the conditions set forth in Article L.22-10-62 of the French <I>Code de
commerce</I>, to decide and implement this authorisation, to specify, if necessary, its terms and, in particular, to place any on or off-market
orders, to earmark or re-earmark purchased shares to the various objectives, in accordance with applicable laws and regulations, to enter
into any agreements, particularly for the purpose of maintaining share purchase and sale registries, to complete any formalities or statements
with any agencies, particularly the French Autorit&eacute; des march&eacute;s financiers and, generally speaking, to take any necessary
action in order to complete the transactions to be carried out pursuant to this authorisation.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting also grants full powers to the Board of
Directors, if the law or the French Autorit&eacute; des march&eacute;s financiers were to extend or supplement to the authorized objectives
for share buyback programs, to inform the public of any changes to the share buyback program concerning the modified objectives, in accordance
with applicable laws and regulations.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting decides that the Board of Directors may
not, without the prior authorisation of the Company&rsquo;s Shareholders&rsquo; Meeting, make use of this authorisation during a public
offering period initiated by a third party for the company&rsquo;s shares, until the end of the offer period.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This authorisation is granted for a period of 18 months from the date of
this Shareholders&rsquo; Meeting. It voids, from that day, any prior authorisation having the same purpose, <I>i.e.</I> any authorisation
relating to the repurchase of its own shares by the Company. This authorisation therefore voids the authorisation granted by the combined
shareholders&rsquo; meeting dated 24 May 2023 pursuant to its twelfth resolution.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Extraordinary Shareholders&rsquo; meeting</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Seventeenth Resolution &ndash; Delegation of authority granted to the
Board of Directors to issue ordinary shares of the Company and/or securities giving access to the share capital of the Company, without
Shareholders&rsquo; preferential subscription rights, within the framework of an offering other than those referred to in paragraph 1&deg;
of Article L.411-2 of the French C<I>ode mon&eacute;taire et financier</I></B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for extraordinary shareholders&rsquo; meetings, after having deliberated and reviewed the report of the Board of Directors
and the special report of the Statutory Auditors, and pursuant to the provisions of Articles L.225-129 to L.225-129-2, L.225-129-5, L.22-10-49,
L.225-135, L.22-10-51, L.225-136, L.22-10-52 and L.228-91 <I>et seq</I>. of the French <I>Code de commerce</I>:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">1. &#8239;&#8239;&#8239;Delegates its authority to
the Board of Directors to decide, without shareholders&rsquo; preferential subscription rights, upon the issue of shares (as the case
may be in the form of American Depositary Shares or American Depositary Receipts) or any other securities giving access to the share capital
of the Company, in euros or any other currencies determined by reference to several currencies, it being specified that said shares grant
the same rights as previously issued shares subject to their dividend entitlement date (<I>date de jouissance</I>). Such issue is to be
carried out through an offering other than those referred to in paragraph 1&deg; of Article L.411-2 of the French <I>Code mon&eacute;taire
et financier</I>, once in full or in various instalments, at the time or times set by the Board of Directors and in the proportions it
shall determine, both in France and outside France. It is hereby further specified that the Board of Directors will also have the option
to sub-delegate all necessary powers to decide and implement the share capital increase to the Chief Executive Officer or, with his prior
approval, to one or more of the Deputy Chief Executive Officers, under the conditions set forth by law;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">2. &#8239;&#8239;&#8239;Decides that any issue of
preferential shares and securities giving access to preferential shares is expressly excluded;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">3. &#8239;&#8239;&#8239;Decides that the nominal amount
of the share capital increases that could potentially be carried out immediately or in the future pursuant to this delegation cannot exceed
an overall nominal amount of &euro;5,000,000 (or, on the basis of the current nominal value of the Company&rsquo;s shares, equal to &euro;0.25,
a maximum amount of 20,000,000 shares), it being specified that this amount will be included in the overall nominal cap amount of &euro;5,000,000
set forth in the twenty-second resolution of the Shareholders&rsquo; Meeting of May 24, 2023 and that this overall nominal amount does
not take into account any adjustments that may potentially be carried out in accordance with applicable legal and regulatory provisions
and, as the case may be, with contractual stipulations providing for other cases of adjustment, in order to preserve the rights of holders
of securities or other rights giving access to the share capital;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">4. &#8239;&#8239;&#8239;Authorises the Board of Directors,
with powers to subdelegate to the Chief Executive Officer or, with the latter&rsquo;s approval, to one ore more Deputy Executive Officer,
under the conditions permitted by law, to increase the number of shares to be issued for each of the issues decided under this resolution,
within thirty (30) days of the close of the subscription period and up to 15% of the initial issue and at the same price as that used
for the initial issue;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">5. &#8239;&#8239;&#8239;Delegates its authority to
the Board of Directors for the purpose of deciding on the issue of debt securities giving access to share capital of the Company to be
issued;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">6. &#8239;&#8239;&#8239;Decides that the overall nominal
amount of securities representing debt securities giving access to the share capital of the Company to be issued that could potentially
be issued pursuant to this delegation will amount to a maximum of &euro;150,000,000 or to the exchange value of this amount in the event
of an issue carried out in any other currency or in any currency unit set through reference to a number of currencies;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">7. &#8239;&#8239;&#8239;Decides to waive the preferential
subscription right of shareholders to the securities to be issued pursuant to this delegation. The Board of Directors will have the option
to grant shareholders a priority subscription period on all or part of the issue of these securities, for a duration and under conditions
it shall determine, in accordance with the provisions of Article L.22-10-51 of the French <I>Code de commerce</I>. This priority period
shall not give rise to the creation of marketable entitlements and shall be exercised in proportion to the number of shares owned by each
shareholder and may potentially be supplemented by a subscription subject to reduction;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">8. &#8239;&#8239;&#8239;Acknowledges that if the subscriptions
have not absorbed all of the issue of shares or securities giving access to the share capital, the Board of Directors may limit the amount
of the transaction to the amount of the subscriptions received;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">9. &#8239;&#8239;&#8239;Acknowledges that, for the
benefit of holders of securities issued pursuant to this resolution and giving access to the share capital of the Company, this delegation
of authority automatically implies shareholders&rsquo; renunciation of their preferential subscription right to shares or securities giving
access to the share capital of the Company that these securities grant rights over immediately or in the future;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">10.&#8239;&#8239;&#8239;Decides that the issue price of the
shares issued pursuant to this delegation will be set at least equal to:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify">The minimum value set by the applicable laws and regulations at the time this authorization is used, that
is currently the weighted average of the prices quoted for the share issued under this authorisation over the three trading days preceding
the beginning of the public offering (within the meaning of Regulation (EU) 2017/1129, as amended) of the shares issued under this authorisation,
eventually reduced by a maximum discount of 10%; or</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify">In the absence of a minimum price stipulated by the laws or regulations applicable on the issue date,
the volume &ndash; weighted average (in the central order book and excluding off-market blocks trades) of the quoted share prices selected
from a period comprising between five and thirty consecutive trading days from among the last thirty trading trading days preceding the
setting of the issuing price, this average may be adjusted to take account of differences in dividends entitlement dates, and may be reduced
by a maximum discount of 15%,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">It being specified that the last thirty trading days referred to in b)
above will be those immediately preceding the setting of the issuing price, which will take place, as the case may be, at the end of the
period during which investors place both firm and indicative subscription orders (i.e.&ldquo;bookbuilding&rdquo; period) and therefore
on the basis of the price appearing in these orders;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">11.&#8239;&#8239;&#8239;Decides that the issue price of the securities giving
access to the share capital will be such that the amount received immediately by the Company, increased, as applicable, by the amount
it would receive in the future, be, for each share issued as a result of the issue of these securities, at least equal to the minimum
issue price defined in the preceding paragraph;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">12. &#8239;&#8239;Decides that the Board of Directors cannot,
unless authorised in advance by the shareholders&rsquo; general meeting, make use of this delegation during a public offering
initiated by a third party targeting the securities of the Company until the end of the offering period;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">13. &#8239;&#8239;Acknowledges that, in the event of the use by
the Board of Directors of the delegation of authority granted by this resolution, the Board of Directors shall report to the
following ordinary shareholders&rsquo; general meeting, in accordance with applicable laws and regulations, on the use made of the
delegation of authority granted by this resolution.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The delegation of authority granted to the Board of Directors is valid
for a term of 18 months as from the date of this Shareholders&rsquo; Meeting. It voids, from that day, any prior authorisation having
the same purpose. This authorisation therefore voids the authorisation granted by the combined shareholders&rsquo; meeting dated 24 May
2023 pursuant to its fourteenth resolution.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Eighteenth Resolution &ndash; Delegation of authority granted to the
Board of Directors to issue, without shareholders&rsquo; preferential subscription rights, ordinary shares of the Company and/or securities
giving access to the share capital of the Company, within the framework of an offering as referred to in paragraph 1&deg; of Article L.411-
of the <I>French Code mon&eacute;taire et financier</I>, known as &ldquo;private placement&rdquo;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for extraordinary shareholders&rsquo; meetings, after having deliberated and reviewed the report of the Board of Directors
and the special report of the Statutory Auditors, and pursuant to the provisions of Articles L.225-129 to L.225-129-2, L.225-129-5, L.22-10-49,
L.225-135, L.22-10-51, L.225-136, L.22-10-52 and L.228-91 <I>et seq</I>. of the French <I>Code de commerce </I>and L.411-2 of the French
<I>Code mon&eacute;taire et financier</I>:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Delegates
its authority to the Board of Directors to decide, without shareholders&rsquo; preferential subscription rights, on the issue of shares
(as the case may be in the form of American Depositary Shares or American Depositary Receipts) or any other securities giving access to
the share capital of the Company, it being specified that said shares grant the same rights as previously issued shares subject to their
dividend entitlement date (<I>date de jouissance</I>). Such issue is to be carried out through an offering referred to in paragraph 1&deg;
of Article L.411-2 of the French <I>Code mon&eacute;taire et financier</I>, once in full or in various instalments, in the proportions
and at the times it shall determine, both in France and outside France, either in euros or in any other currency or any monetary unit
established by reference to several currencies. It is hereby further specified that the Board of Directors will also have the option to
sub-delegate all necessary powers to decide on and implement the share capital increase to the Chief Executive Officer or, with his prior
approval, to one or more of the Deputy Chief Executive Officers, under the conditions set forth by law;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that any issue of preferential shares and securities giving access to preferential shares is expressly excluded;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that the nominal amount of the share capital increases that could potentially be carried out immediately and/or in the future pursuant
to this delegation cannot exceed an overall nominal amount of &euro;5,000,000 (or, on the basis of the current nominal value of the Company&rsquo;s
shares, equal to &euro;0.25, a maximum amount of 20,000,000 shares), it being specified that this amount will be included in the overall
nominal cap amount of &euro;5,000,000 set forth in the twenty-second resolution of the Shareholders&rsquo; Meeting of May 24, 2023 and
that this overall nominal amount does not take into account any adjustments that may potentially be carried out in accordance with applicable
legal and regulatory provisions and, as the case may be, with contractual stipulations providing for other cases of adjustment, in order
to preserve the rights of holders of securities or other rights giving access to the share capital;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Authorises
the Board of Directors, with powers to subdelegate to the Chief Executive Officer or, with the latter&rsquo;s approval, to one or more
Deputy Executive Officer, under the conditions permitted by law, to increase the number of shares to be issued for each of the issues
decided under this resolution, within thirty (30) days of the close of the subscription period and up to 15% of the initial issue and
at the same price as that used for the initial issue;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that, the issue of capital securities carried out pursuant to this delegation will not, in any event, exceed the limit set out by the
applicable law regulation on the issue date, (<I>i.e.</I> at the present time 20% <I>per annum</I>) it being specified that thislimit
shall be assessed at the time of the issue and shall apply to the share capital as adjusted according to the transactions affecting it
after this Shareholders&rsquo; Meeting;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Delegates
its authority to the Board of Directors for the purpose of deciding on the issue of debt securities giving access to share capital of
the Company to be issued;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that the overall nominal amount of securities representing debt securities giving access to the share capital of the Company to be issued
that could potentially be issued pursuant to this delegation will amount to a maximum of &euro;150,000,000 or to the exchange value of
this amount in the event of an issue carried out in any other currency or in any account unit set through reference to a number of currencies;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&#8239;Decides
to waive the preferential subscription right of shareholders to the securities to be issued pursuant to this delegation;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Acknowledges
that if the subscriptions have not absorbed all of the issue of shares or securities giving access to the share capital, the Board of
Directors may limit the amount of the transaction to the amount of the subscriptions received;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">10.&#8239; <FONT STYLE="font-size: 10pt"> Acknowledges
that, for the benefit of holders of securities issued pursuant to this resolution and giving access to the share capital of the
Company, this delegation of authority automatically implies shareholders&rsquo; renunciation of their preferential subscription
right to shares or securities giving access to the share capital that these securities grant rights over immediately or in the
future;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">11. &#8239;<FONT STYLE="font-size: 10pt">Decides that the issue
price of the share issued pursuant to this delegation will be set at least equal to</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify">The minimum value set by the applicable laws and regulations at the time this authorization is used, that
is currently the weighted average of the prices quoted for the share issued under this authorisation over the three trading days preceding
the beginning of the public offering (within the meaning of Regulation (EU) 2017/1129, as amended) of the shares issued under this authorisation,
eventually reduced by a maximum discount of 10%; or</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify">In the absence of a minimum price stipulated by the laws or regulations applicable on the issue date,
the volume &ndash; weighted average (in the central order book and excluding off-market blocks trades) of the quoted share prices selected
from a period comprising between five and thirty consecutive trading days from among the last thirty trading days preceding the setting
of the issuing price, this average may be adjusted to take account of differences in dividends entitlement dates, and may be reduced by
a maximum discount of 15%,</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">It being specified that the last thirty trading days referred to in b)
above will be those immediately preceding the setting of the issuing price, which will take place, as the case may be, at the end of the
period during which investors place both firm and indicative subscription orders (i.e.&ldquo;bookbuilding&rdquo; period) and therefore
on the basis of the price appearing in these orders;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">12. <FONT STYLE="font-size: 10pt">&#8239;Decides that the issue
price of the securities giving access to the capital will be such that the amount received immediately by the Company, increased, as applicable,
by the amount it is likely to receive in the future, be, for each share issued as a result of the issue of these securities, at least
equal to the minimum issue price defined in the preceding paragraph;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">13. <FONT STYLE="font-size: 10pt">&#8239;&#8239;Decides that the Board
of Directors cannot, unless authorised in advance by the shareholders&rsquo; general meeting, make use of this delegation in the context
of a public offering initiated by a third party targeting the securities of the Company until the end of the offering period; and</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">14. <FONT STYLE="font-size: 10pt">&#8239;Acknowledges that,
in the event of the use by the Board of Directors of the delegation of authority granted by this resolution, the Board of Directors shall
report to the subsequent ordinary shareholders&rsquo; general meeting, in accordance with the laws and regulations, regarding the use
made of the delegation of authority granted by this resolution.</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The delegation of authority granted to the Board of Directors is valid
for a term of 18 months as from the date of this Shareholders&rsquo; Meeting. It voids, from that day, any prior authorisation having
the same purpose. This authorisation therefore voids the authorisation granted by the combined shareholders&rsquo; meeting dated 24 May
2023 pursuant to its fifteenth resolution.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Nineteenth Resolution &ndash; Determination of the issue price, in accordance
with resolutions n&deg;17 and 18 above mentioned, of the ordinary shares and/or of the securities giving access to the share capital of
the Company, in the event of a renunciation of shareholders&rsquo; preferential subscription rights</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for extraordinary shareholders&rsquo; meetings, after having deliberated and reviewed the report of the Board of Directors
and the special report of the Statutory Auditors, and pursuant to the provisions of paragraph 2 of Article L.22-10-52, of the French <I>Code
de commerce</I>, and up to the limit fixed by the applicable law and regulation at the date of the issue (i.e. 10% of the capital per
annum as of today) it being specified that this limit shall be assessed at the time of the issue and shall apply to the share capital
as adjusted according to the transactions affecting it subsequent to this Shareholders&rsquo; Meeting:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Authorizes
the Board of Directors, with the option to sub-delegate, under the conditions set forth by law, to derogate from the conditions for setting
the price provided for in paragraph 10.a) of the seventeenth resolution and 11.a) of the eighteenth resolution of this Shareholders&rsquo;
Meeting and to set the price of the shares issued directly or through the issue of any other securities giving access to the share capital,
after taking into account any market opportunities, at a price that is at least equal to the volume-weighted average (in the central order
book excluding off-market block trades) of the quoted share prices selected from a period comprisingincluding between five and thirty
consecutive trading days among the last thirty trading days preceding the setting of the issuing price, this average may be adjustedto
take into ofdifferences in dividend entitlement dates, and may be reduced by a maximum discount of 15%;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Specifies
that the last thirty trading days above will be those immediately preceding the setting of the issuing price, which will take place, as
the case may be, at the end of the period during which investors place both firm and indicative subscription orders (i.e. &ldquo;bookbuilding&rdquo;
period) and therefore on the basis of the price appearing in these orders;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Acknowledges
that, in the event of use by the Board of Directors of the delegation of authority granted by this resolution, the Board of Directors
shall prepare a supplementary report, certified by the Statutory Auditors, describing the final terms of the transaction and providing
the criteria for assessing the actual impact on the shareholder&rsquo;s situation.</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The delegation of authority granted to the Board of Directors is valid
for a term of 18 months as from the date of this Shareholders&rsquo; Meeting. It voids, from that day, any prior authorisation having
the same purpose. This authorisation therefore voids the authorisation granted by the combined shareholders&rsquo; meeting dated 24 May
2023 pursuant to its sixteenth resolution.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Twentieth Resolution &ndash; Delegation of authority granted to the
board of Directors to issue ordinary shares and/or securities giving access to the share capital of the Company without preferential subscription
rights and for the benefit of a category of persons</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for extraordinary shareholders&rsquo; meetings, after having deliberated and reviewed the report of the Board of Directors
and the special report of the Statutory Auditors, and pursuant to the provisions of Articles L.225-129 to L.225-129-2, L.225-129-5, L.22-10-49,
L.225-135, L.225-135-1, L.22-10-51, L.225-138, L.228-91 <I>et seq</I>. of the French <I>Code de commerce</I>:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Delegates
its authority to the Board of Directors to decide to increase the share capital, without shareholders&rsquo; preferential subscription
rights, once in full or in various instalments, for an overall nominal amount of &euro;5,000,000 (or, on the basis of the current nominal
value of the Company&rsquo;s shares, equal to &euro;0.25, a maximum amount of 20,000,000 shares), by the issue of shares (as the case
may be in the form of American Depositary Shares or American Depositary Receipts) and any other securities giving access to the capital
of the Company, the said shares granting the same rights as previously issued shares subject to their dividend entitlement date (<I>date
de jouissance</I>), in euros or any other currencies determined by reference to several currencies, in France or abroad, it being specified
that this amount will be included in the overall nominal cap amount of &euro;5,000,000 set forth in the twenty-second resolution of the
Shareholders&rsquo; Meeting of May 24, 2023 and that this overall nominal amount does not take into account any adjustments that may potentially
be carried out in accordance with applicable legal and regulatory provisions and, as the case may be, with contractual stipulations providing
for other cases of adjustment, in order to preserve the rights of holders of securities or other rights giving access to the share capital;
it being specified that the Board of Directors will have the option to sub-delegate all necessary powers to decide and implement (and,
as the case may be, postpone) the share capital increase to the Chief Executive Officer or, with his prior approval, to one or more of
the Deputy Chief Executive Officers, under the conditions set forth by law;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Authorises
the Board of Directors, with powers to subdelegate to the Chief Executive Officer or, with the latter&rsquo;s approval, to one or more
Deputy Executive Officer, under the conditions permitted by law, to increase the number of shares to be issued for each of the issues
decided under this resolution, within thirty (30) days of the close of the subscription period and up to 15% of the initial issue and
at the same price as that used for the initial issue;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that any issue of preferential shares and securities giving access to preferential shares is expressly excluded;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Delegates
its authority to the Board of Directors for the purpose of deciding on the issue of securities entitling their holder to debt securities
giving access to share capital of the Company to be issued;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that the overall nominal amount of securities representing debt securities giving access to the share capital of the Company or to debt
securities that could potentially be issued pursuant to this delegation will amount to a maximum of &euro;150,000,000 or to the exchange
value of this amount in the event of an issue carried out in any currency or in any other currency unit set through reference to a number
of currencies;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
to waive the preferential subscription right of shareholders to the securities to be issued pursuant to this resolution and to reserve
the right to subscribe:</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1)</TD><TD STYLE="text-align: justify">In the context of an industrial or strategic agreement with the Company to:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify">industrial or commercial companies of the pharmaceutical/biotech sector, or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify">investment fund companies or fund management companies or collective savings managing funds established
under French or foreign law, or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: justify">any other legal entity (including a trust) or physical person, investing in the pharmaceutical/biotech
sector; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2)</TD><TD STYLE="text-align: justify">In the context of an offering referred to in paragraph 1&deg; of Article L.411-2 of the French <I>Code
mon&eacute;taire et financier</I> in respect of French investors and equivalent provisions for foreign investors to:</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify">industrial or commercial companies of the pharmaceutical/biotech sector, or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify">investment fund companies or fund management companies or collective savings managing funds established
under French or foreign law, or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: justify">any other legal entity (including a trust) or physical person, investing in the pharmaceutical/biotech
sector,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 56.7pt">meeting, in each case a), b) and c) listed above, the criteria
to participate in such an offering, or</P>

<P STYLE="margin: 0pt 0 0pt 56.7pt; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify">investment services providers of French or foreign law likely to secure such an offering; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3)</TD><TD STYLE="text-align: justify">In the context of a debt financing transaction with credit institutions or other institutions providing
such financing, to the lenders involved.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Acknowledges
that, for the benefit of holders of securities issued pursuant to this resolution and giving access to the share capital of the Company,
this delegation of authority automatically implies shareholders&rsquo; renunciation of their preferential subscription right to shares
or securities giving access to the share capital that these securities grant rights;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that the Board of Directors, with the faculty to subdelegate to the Chief Executive Officer or, with the latter&rsquo;s approval, to one
or more Deputy Executive Officer, under the conditions permitted by law, will set the list of the beneficiaries within the category of
beneficiaries mentioned above to the benefit of which the preferential subscription right have been waived and will set the characteristics,
the amount and the terms of any issue as well as the terms and conditions for paying up the issued shares. In particular, it will determine
the number of shares to be issued to each beneficiary and will set, given the information contained in its report, the subscription price
of such securities, their entitlement date, provided that the sum received or to be received by the Company for each share issued under
this delegation shall be at least equal to the volume-weighted average (in the central order book and excluding off-market block trades)
of the quoted share prices selected from a period comprisingincluding between five and thirty consecutive trading days among the last
thirty trading days preceding the setting of the issuing price, this average may be adjustedto take into ofdifferences in dividend entitlement
dates, and may be reduced by a maximum amount of 15%;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Specifies
of the quoted share prices selected from a period comprisingincluding between five and thirty consecutive trading days among the last
thirty trading days preceding the setting of the issuing price, this average may be adjustedto take into ofdifferences in dividend entitlement
dates, and may be reduced orders;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">10. <FONT STYLE="font-size: 10pt">&#8239;&#8239;Decides that the Board
of Directors cannot, unless authorised in advance by the shareholders&rsquo; general meeting, make use of this delegation in the context
of a public offering initiated by a third party targeting the securities of the Company until the end of the offering period;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">11. &#8239;&#8239;<FONT STYLE="font-size: 10pt">The Board of Directors
will have the option under the terms set out in paragraph 1, to sub-delegate to the Chief Executive Officer and, with his prior approval,
to one or more of the Deputy Chief Executive Officers, the power to take all or part of the decisions mentioned in the paragraphs above
and, as the case may be, in accordance with indicative parameters which it may have adopted; </FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">12. <FONT STYLE="font-size: 10pt">&#8239;Acknowledges that,
in the event of use by the Board of Directors of the delegation of authority granted by this resolution, the Board of Directors shall
report to the following ordinary shareholders&rsquo; general meeting, in accordance with the laws and regulations, regarding the use made
of the delegation of authority granted by this resolution.</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The delegation granted to the Board of Directors pursuant to the resolution
is valid for a term of 18 months as from the date of this Shareholders&rsquo; Meeting. It voids, from that day, any prior delegation having
the same purpose. This delegation therefore voids the authorisation granted by the combined shareholders&rsquo; meeting dated 24 May 2023
pursuant to its seventeenth resolution.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B></B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Twenty-first Resolution &ndash; Delegation of authority granted to the
Board of Directors to issue ordinary shares and/or securities giving access to the share capital of the company, as compensation for contributions
in kind comprised of equity securities or securities giving access to the share capital</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for extraordinary shareholders&rsquo; meetings, after having deliberated and reviewed the report of the Board of Directors
and the special report of the Statutory Auditors, and pursuant to the provisions of Articles L.225-129 to L.225-129-2, L.225-129-5, L.225-147,
L.225-147-1, L.22-10-35, L.228-91 <I>et seq</I>. of the French <I>Code de commerce</I>:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Delegates
its authority to the Board of Directors for the purpose of deciding on the issue of shares (as the case may be in the form of American
Depositary Shares or American Depositary Receipts) or any other securities giving access to the share capital of the Company, in order
to offer compensation for contributions in kind granted to the Company and comprised of equity securities or securities giving access
to the share capital, when the provisions of Article L.22-10-54 of the French <I>Code de commerce</I> do not apply and decides, as necessary,
to waive the preferential subscription right of shareholders to these shares and securities to be issued, for the benefit of the holders
of these securities;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that the overall nominal amount of the capital increases that may be carried out immediately or at a later date under this delegation
may not exceed an overall nominal amount of &euro;5,000,000 (or, on the basis of the current nominal value of the Company&rsquo;s shares,
equal to &euro;0.25, a maximum amount of 20,000,000 shares), it being specified that this amount will be included in the overall nominal
cap amount of &euro;5,000,000 set forth in the twenty-second resolution of the Shareholders&rsquo; Meeting of May 24, 2023 and that this
overall nominal amount does not take into account any adjustments that may potentially be carried out in accordance with applicable legal
and regulatory provisions and, as the case may be, with contractual stipulations providing for other cases of adjustment, in order to
preserve the rights of holders of securities or other rights giving access to the share capital;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that the issue of share capital securities carried out pursuant to this resolution will not, in any event, exceed the limit set out by
the applicable law and regulation on the issue date, (<I>i.e.</I> at the present time 10% of the share capital), it being specified that
this limit shall be assessed at the time of the issue and shall apply to the share capital as adjusted according to the transactions affecting
it after this Shareholders&rsquo; Meeting;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that any issue of preferential shares and securities giving access to preferential shares is expressly excluded;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Delegates
its authority to the Board of Directors for the purpose of deciding on the issue of debt securities giving access to share capital of
the Company to be issued;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that the overall nominal amount of securities representing debt securities giving access to the share capital of the Company to be issued
that could potentially be issued pursuant to this delegation will amount to a maximum of &euro;150,000,000 or to the exchange value of
this amount in the event of an issue carried out in any currency or in any currency unit set through reference to a number of currencies;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Acknowledges
that this delegation of authority implies shareholders&rsquo; renunciation of their preferential subscription rights to ordinary shares
to which the securities that would be issued based on this delegation may grant rights over immediately or in the future;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that the Board of Directors will have full powers, with the option to sub-delegate under the conditions set forth by law, to enforce this
resolution and, in particular, to set the list of securities contributed, approve or reduce the valuation of contributions and the granting
of specific advantages, to set, as the case may be, the cash amount to be paid, and acknowledge the number of securities contributed to
the exchange;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that the Board of Directors cannot, unless authorised in advance by the shareholders&rsquo; general meeting, make use of this delegation
in the context of a public offering initiated by a third party targeting the securities of the Company until the end of the offering period;
and</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">10. <FONT STYLE="font-size: 10pt">Acknowledges that,
in the event of the use by the Board of Directors of the delegation of authority granted by this resolution, the Board of Directors shall
report to the following ordinary shareholders&rsquo; general meeting, in accordance with the laws and regulations, regarding the use made
of the delegation of authority granted by this resolution.</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The delegation of authority granted to the Board of Directors pursuant
to this resolution is valid for a term of 18 months as from the date of this Shareholders&rsquo; Meeting. It voids, from that day, any
prior authorisation having the same purpose. This authorisation therefore voids the authorisation granted by the combined shareholders&rsquo;
meeting dated 24 May 2023 pursuant to its twentieth resolution.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Twenty-second Resolution &ndash; Delegation of power granted to the
Board of Directors to cancel all or part of the shares held by the Company under the share buyback authorisation</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for extraordinary shareholders&rsquo; meetings, after having deliberated and reviewed the report of the Board of Directors
and the special report of the Statutory Auditors, subject to adoption of the authorisation to buy back the Company&rsquo;s own shares
set out in the sixteenth resolution, authorise the Board of Directors, in accordance with the provisions of Articles L.22-10-62 <I>et
seq</I> of the French Code du Commerce, to cancel in the proportions and at the times it sees fit, on one or more occasions, all or part
of the Company&rsquo;s shares held by it under an authorisation to purchase said shares granted by the Shareholders&rsquo; Meeting, and
to reduce the Company&rsquo;s share capital by the aggregate par value of shares cancelled, up to a limit of 10% of the share capital
per 24-months period, it being noted that this limit applies to the Company&rsquo;s share capital, which may be adjusted to take into
consideration operations affecting the share capital subsequently to this Shareholder&rsquo;s Meeting.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting gives full powers to the Board of Directors,
with powers to subdelegate under the conditions set forth by law, to carry out the aforementioned capital reduction, record its completion,
deduct the difference between the purchase price of the cancelled shares and their par value from all reserves and premiums, amend the
articles of association accordingly, make all declarations with the Autorit&eacute; des March&eacute;s Financiers, complete all other
formalities and generally do whatever is necessary.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The delegation of powers granted to the Board of Directors pursuant to
this resolution is valid for a term of 18 months as from the date of this Shareholders&rsquo; Meeting. It voids, from that day, any prior
authorisation having the same purpose. This authorisation therefore voids the authorisation granted by the combined shareholders&rsquo;
meeting dated 24 May 2023 pursuant to its twenty-seventh resolution.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Twenty-third Resolution &ndash; Authorisation granted to the Board of
Directors to allocate options to subscribe and/or purchase shares</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for extraordinary shareholders&rsquo; meetings, after having deliberated and reviewed the report of the Board of Directors
and the special report of the Statutory Auditors, and pursuant to Articles L.225-177 to L.225-185 and L.22-10-56 to L.22-10-58 of the
French <I>Code de commerce</I>;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">1. &#8239;&#8239;&#8239;Authorises the Board of Directors to grant, on one or more occasions,
subject to the abstention periods provided for by law, options granting entitlement to the subscription of new shares of the Company to
be issued by means of a share capital increase or to the purchase of existing Company&rsquo;s shares resulting from buy-backs realized
pursuant to applicable law, to the benefit of employees and executive officers of the Company or of the group as provided in Article L.225-180
of the French <I>Code de commerce</I>, or of some of them, and thus approves the putting in place by the Board of Directors of one or
more share subscription and/or purchase options plans within the frame set out below;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">2. &#8239;&#8239;&#8239;Decides that the options that may be granted pursuant to this authorization
will not give rights, upon exercise, to the subscription or purchase of a total number of shares exceeding 600,000 shares that is, as
the case may be, a maximum share capital increase of &euro;150,000; it being specified that this cap of 600,000 shares: (i) does not take
into account any adjustment that may be made in accordance with applicable legal and regulatory provisions and, as the case may be, with
the contractual provisions providing for other adjustment cases to preserve the rights of the holders of securities or other rights giving
access to the share capital; and (ii) shall be adjusted to take into account all transactions lowering the nominal value of the shares
or increasing the number of shares that could take place before the allocation of the options;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">3. &#8239;&#8239;&#8239;Decides, subject, in the case of corporate officers, to the provisions
of Article L. 225-185 paragraph 4 of the French <I>Code du commerce</I>, that the time period for exercising the options shall not exceed
10 years from the date of the allocation;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">4. &#8239;&#8239;&#8239;Decide that the exercise price of the options granted pursuant to this
delegation shall be set on the day the options are granted by the Board of Directors, it being specified that the exercise price of the
options shall not be (i) lower than 80% of the average of the share price during the twenty trading days preceding the date upon which
the options are granted; and (ii) only for options to purchase existing shares, lower than 80% of the average purchase price of the shares
held by the Company, pursuant to Article L.22-10-62 of the French <I>Code de commerce;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">5. &#8239;&#8239;&#8239;Decides that the exercise price may be modified throughout the duration
of the options only in case of implementation of the measures required to protect the interests of the beneficiaries of the options, pursuant
to Article L.225-181 of the French <I>Code de commerce;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">6. &#8239;&#8239;&#8239;Acknowledges that, for the benefit of the beneficiaries
of the options, the Shareholders&rsquo; Meeting&rsquo;s decision automatically implies shareholders&rsquo; renunciation of their preferential
subscription rights to shares that shall be issued as the options to subscribe are exercised;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">7. &#8239;&#8239;&#8239;Decides to grant full powers to the Board of Directors, with the option
to delegate and sub-delegate under the conditions set forth by law, notably:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">to determine the conditions for the allocation of the options, the number and the identity of the beneficiaries
and the number of options granted to each of them;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">to set, within the above-specified limits, the options&rsquo; exercise price and the time period during
which the options may be exercised;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">to set the exercise conditions and notably the performance conditions to which the exercise of the options
allocated to the executive officers and directors of the Company and of its subsidiaries shall be subject to;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">to impose, as the case may be, a time period during which the options shall not be exercised and/or a
time period during which the acquired shares may not be transferred;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">when determining the features of each plan, to take into account legal requirements, notably tax ones,
applicable depending on the jurisdiction where the beneficiaries are located, notably, as far as the United States are concerned, the
relevant provisions of the Federal Tax Code;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">establish the stock options plans;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">to temporarily suspend the exercise of the options in given circumstances;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">where necessary, take all measures to reserve the rights of option beneficiaries in accordance with any
legal or regulatory provisions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">set the dividend entitlement date (<I>date de jouissance</I>), even retroactive, of the shares to be issued
on the exercise of the options;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">at its sole initiative, deduct the capital increase expenses on the amount of the premium relating to
these issuances and to deduct from this amount the sums required to raise the legal reserve to one-tenth of the new share capital after
each increase;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">to record the completion of the increase(s) in the share capital resulting from the exercise of the options,
complete any acts and formalities in order to finalize the increase(s) in share capital realized pursuant to this authorization, amend
the articles of association accordingly and more generally take all decisions required in the context of this authorization, grant all
delegations, and do all that is needed.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Board of Directors shall notify the shareholders each year during the
shareholders&rsquo; meeting, under the conditions set forth by law, of the transactions carried out in pursuant to this resolution.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting acknowledges that this delegation voids,
from that day, any prior delegation of authority having the same purpose. This delegation therefore voids the delegation granted by the
combined shareholders&rsquo; meeting held on 24 May 2023 pursuant to its twenty-fourth resolution.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This authorization is granted for a period of 38 months from the date of
this Shareholders&rsquo; Meeting.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Twenty-fourth Resolution &ndash; Authorization granted to the Board
of Directors to allocate free, existing or new, shares</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for extraordinary shareholders&rsquo; meetings, after having deliberated and reviewed the report of the Board of Directors
and the special report of the Statutory Auditors, and pursuant to the provisions of Articles L.225-197-1 to L.225-197-6 and L.22-10-59
to L.22-10-60 of the French <I>Code de commerce</I>, authorizes the Board of Directors to proceed, in one or several allocations, with
the free allocation of a maximum of 150,000 common shares, existing or to be issued, with a nominal value of &euro;0.25 each, for the
benefit of the employees and the executive officers of the Company or the entities or groups referred to in Article L.225-197-2, or for
the benefit of some of them (the &ldquo;<B>Free Shares</B>&rdquo;).</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.25pt"></TD><TD STYLE="width: 18pt">(1)</TD><TD STYLE="text-align: justify">Share capital increase</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The definitive acquisition of the totality of the Free Shares, in the case
of new shares, will result in one or several capital increases of &euro;37,500 which are authorized by this Shareholders&rsquo; Meeting,
it being specified that this amount does not take into account any adjustments that may potentially be carried out in accordance with
applicable legal and regulatory provisions and, as the case may be, with contractual stipulations providing for other cases of adjustment,
in order to preserve the rights of holders of securities or other rights giving access to the share capital.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The capital increase(s) that will result from the creation of the Free
Shares will be implemented by way of special incorporation of all or part of the reserve accounts available and, in particular, of the
account &ldquo;share issue premium&rdquo;. The Shareholders&rsquo; Meeting acknowledges that this decision implies shareholders&rsquo;
renunciation of their rights, for the benefit of holders of Free Shares, to the said reserves.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.25pt"></TD><TD STYLE="width: 18pt">(2)</TD><TD STYLE="text-align: justify">Acquisition and retention periods</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Board of Directors shall determine, for each allocation, a vesting
period of at least one year after which the acquisition of existing or new shares will become definitive, followed, if deemed useful or
necessary by the Board of Directors, by a retention period of a duration it shall determine and which shall run from the definitive acquisition
of the existing or new shares; it being specified that the cumulated duration of the vesting period and, as the case may be, of the retention
period, shall be of at least three years.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The definitive acquisition of the Free Shares must be subject to a condition
of the beneficiary&rsquo;s presence in the Company or its subsidiaries as employee and/or executive officer or the member of the administrative
or supervisory bodies (subject to legal exceptions or a change of control of the Company and it being understood that the Board of Directors
may, if necessary, waive this condition on an individual basis) and, as the case may be, to the fulfilment of performance conditions that
the Board of Directors may determine upon allocation, as is specified below.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.25pt"></TD><TD STYLE="width: 18pt">(3)</TD><TD STYLE="text-align: justify">Delegation of powers to the Board of Directors</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Shareholders' Meeting grants full powers to the Board of Directors,
with the option to sub-delegate under the conditions set forth by law, to implement the allocation of Free Shares, including:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">to determine the conditions of eligibility, the number and the identity of the beneficiaries et the number
of Free Shares allocated to each of them;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">determine within the aforementioned limits, the acquisition period and, if applicable, the Free Shares
retention period;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">to determine, in particular for the executive officers and certain directors of the Company and its subsidiaries,
as the case may be, the performance conditions to which the definitive acquisition of the Free Shares will be subject;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">to establish the Free Shares plans;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">to take all necessary measures in order to preserve the rights of the holders of Free Shares pursuant
to any legal or regulatory provisions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">to set the dividend entitlement date (date de jouissance), even retroactively, of the Free Shares to be
issued; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">to record the completion of the increase(s) in the share capital resulting from the definitive acquisition
of Free Shares, complete any act and formalities in order to finalize the increase(s) in share capital realized pursuant to this authorization,
amend the articles of association accordingly and more generally take all decisions required in the context of this authorization, grant
all delegations, and do all that is needed.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">The Shareholders&rsquo; Meeting acknowledges that this delegation voids, from that day, any
prior delegation of authority having the same purpose. This delegation therefore voids the delegation granted by the combined shareholders&rsquo;
meeting held on 24 May 2023 pursuant to its twenty-fifth resolution.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This authorization may be used within a period of 38 months from the date
of this Shareholders&rsquo; Meeting.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Twenty-fifth Resolution &ndash; Delegation of authority granted to the
Board of Directors for the purpose of issuing ordinary shares and/or securities giving access to the share capital of the Company for
the benefit of the members of a company&rsquo;s saving plan</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for extraordinary shareholders&rsquo; meetings, after having deliberated and reviewed the report of the Board of Directors
and the special report of the Statutory Auditors, within the framework of the provisions of Articles L.3332-18 <I>et seq</I>. of the French
<I>Code du travail </I>and of Article L.225-138-1 of the French <I>Code de commerce </I>and in accordance with the provisions of Article
L.225-129-6 of that same <I>Code</I>:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Delegates
all powers to the Board of Directors for the purpose of increasing the Company&rsquo;s share capital, either once in full or in a number
of instalments, in the proportions and at the times it shall determine, by a maximum nominal amount of &euro;12,500 (or, on the basis
of the current nominal value of the Company&rsquo;s shares, equal to &euro;0.25, a maximum amount of 50,000 shares), through the issue
of shares or other securities giving access to the share capital, reserved to members of a company savings plan of the Company and of
French or foreign companies that are related to the Company under the conditions set forth in Article L.225-180 of the French <I>Code
de commerce</I> and Article L.3344-1 of the French <I>Code du travail</I>;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that the Board of Directors will set the subscription price of the new shares, that will be equal to 80% of the average of the first listed
prices of the Company&rsquo;s share during the twenty trading days preceding the date of the decision setting the opening date for subscription
when the duration of the retention period stipulated by the savings plan pursuant to Articles L.3332-25 <I>et seq.</I> of the French <I>Code
du travail</I> is less than 10 years, and to 70% of this average when said retention period is greater than or equal to 10 years. Nevertheless,
the Shareholders&rsquo; Meeting expressly authorizes the Board of Directors, if it thinks it appropriate, to reduce or cancel the above-mentioned
discounts, within legal and regulatory limits, in order to take into account, among others, the applicable legal, accounting, tax and
social security considerations in the countries where the members of a company&rsquo;s savings plan benefiting from the capital increase
reside;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that the Board of Directors will also have the power to substitute all or part of the discount with an allocation of free shares or other
securities giving access to the Company&rsquo;s share capital, either existing or to be issued, it being specified that the total benefit
resulting from the allocation and, as applicable, the discount mentioned above, may not exceed the total benefit that members of the savings
plan would have received if that shortfall had been 20% or 30% when the retention period stipulated by the plan pursuant to Articles L.3332-25
<I>et seq</I>. of the French <I>Code du travail</I> is greater than or equal to ten years;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides,
pursuant to Article L.3332-21 of the French <I>Code du travail</I>, that the Board of Directors may also provide for the allocation, free
of charge, of new or existing shares or other new or existing securities giving access to the Company&rsquo;s share capital, as an employer
matching contribution, provided that their equivalent monetary value, valued at the subscription price, will not have the effect of exceeding
the limits provided for in Articles L.3332-10 <I>et seq.</I> of the French <I>Code du travail</I>;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
to waive, in favour of members of a company&rsquo;s savings plan, the shareholders&rsquo; preferential subscription rights to the new
shares to be issued or to other securities giving access to the share capital, and to the securities to which such securities issued pursuant
to this resolution give access to;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that the characteristics of the other securities giving access to the share capital will be decided by the Board of Directors, under the
conditions set forth by applicable regulations;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Decides
that the Board of Directors shall have all powers, with the power to delegate or sub-delegate under the conditions set forth by law, to
implement this resolution and, in particular, with respect to determining the terms and conditions of the transactions and deciding on
the dates and terms of the issues to be carried out pursuant to this delegation, setting the opening and closing dates of the subscription
periods, the dividend entitlement dates (<I>dates de jouissance</I>) of the issued securities, determining the terms and conditions for
paying up the shares and other securities giving access to the Company&rsquo;s share capital, determining the timeframe for such paying
up of shares and, as applicable, of the securities giving access to the Company&rsquo;s share capital, requesting the created securities&rsquo;
admission to trading on the stock market wherever appropriate, announcing the completion of the share capital increases in the amount
of the shares that will actually be subscribed, completing, directly or through an agent, any transactions and formalities in connection
with share capital increases and, at its sole discretion and if it sees fit, deducting the costs of the share capital increases from the
amount of premiums associated with those increases and withholding from that amount the sums necessary to increase the legal reserve to
one-tenth of the new share capital after each share capital increase; and </FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0in; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0in">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; Acknowledges
that this delegation voids, from that day, any prior delegation of authority having the same purpose. This delegation granted to the Board
of Directors is valid for a term of 26 months as from the date of this Shareholders&rsquo; Meeting.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Twenty-sixth Resolution &ndash; Amendment of Article 4.2 of the Company&rsquo;s
articles of association to complete the description of its <I>raison d&rsquo;&ecirc;tre</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for extraordinary shareholders&rsquo; meetings, having reviewed the report of the Board of Directors and the draft amendment
to Article 4.2 of the Company&rsquo;s articles of association, decides to complete the Article 4.2 of the Company&rsquo;s article of association
by adding the following paragraph at the end of the article:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&ldquo;The Company aims to generate a positive and significant social,
societal and environmental impact in the course of its activities. As part of this approach, the Board of Directors undertake to take
into consideration (i) the social, societal, environmental consequences of its decisions on all of the company&rsquo;s stakeholders, and
(ii) the consequences of its decision on the environment.&rdquo;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Twenty-seventh Resolution &ndash; Amendment of Article 18 II of the
Company&rsquo;s articles of association to facilitate Board Meetings</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for extraordinary shareholders&rsquo; meetings, having reviewed the report of the Board of Directors and of the draft amendment
to Article 18 II of the Company&rsquo;s articles of association, decides to delete the following text from the third Alinea of the II
of Article 18:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&ldquo;Except when the Board of Directors is gathered to proceed to operations
referred to in Articles L.232-1 et L.233-16 of the French <I>Code du commerce</I>&rdquo;.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The rest of Article 18 II of the Company&rsquo;s articles of association
remains unchanged.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Twenty-eight Resolution - Amendment of Article 26 of the Company&rsquo;s
articles of association to remove the statutory obligation to appoint one or more alternate Statutory Auditors</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting, deciding under the quorum and majority
requirements for extraordinary shareholders&rsquo; meetings, having reviewed the report of the Board of Directors, pursuant to the provisions
of Article L.823-1 of the French <I>code de commerce</I> and of the draft amendment to Article 26 of the Company&rsquo;s articles of association
decides to amend the Company&rsquo;s articles of association as to:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">1. Delete the statutory obligation to appoint one or more alternate Statutory
Auditors;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">2. Consequently decides to delete the second Alinea of Article 26 I of
the Company&rsquo;s articles of association :</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&ldquo;It appoints, in accordance with the law applicable, one or more
alternate Statutory Auditors meant to replace the incumbent in the event of death, resignation or incapacity&rdquo;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">And to replace it with the following paragraph:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&ldquo;Where the Statutory Auditor is a natural person or a one-person
company, one or more alternate Statutory Auditors are appointed under the same conditions, to replace the incumbents in the even of refusal,
incapacity, resignation or death&rdquo;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The rest of Article 26 of the Company&rsquo;s articles of association remains
unchanged.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B></B></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>Ordinary Shareholder&rsquo;s Meeting</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Twenty-ninth Resolution </B>- <B>Powers to complete formalities</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting grants full powers to the holder of an
original, a copy or an extract of the minutes of this Shareholders&rsquo; Meeting to complete all legal and regulatory formalities and
make all filings and publications relating to the above-mentioned resolutions required by applicable laws.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B></B></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"><B></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>A. Preliminary formalities to complete in order to participate to the
Shareholders&rsquo; Meeting</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In accordance with Article R.22-10-28 of the French <I>Code de commerce</I>,
the right to participate in the Shareholders&rsquo; Meeting is justified by registering the securities in the name of the shareholder
or the intermediary registered on their behalf (in application of the seventh paragraph of Article L.228-1 of the French <I>Code de commerce</I>),
on the second day preceding the Shareholders&rsquo; Meeting at midnight, Paris time (which will be the May 20, 2024) either in the registered
(<I>au nominatif</I>) securities accounts kept by the Company (or its agent), or in the bearer (<I>au porteur</I>) securities accounts
kept by the authorized intermediary.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The registration of the securities in the bearer (<I>au porteur</I>) securities
accounts kept by the financial intermediaries is evidenced by a participation certificate issued by the latter (if necessary by electronic
means) under the conditions provided for in Article R.22-10-28 of the French <I>Code de commerce</I> (with reference to Article R.&nbsp;225-61
of the same <I>Code</I>), in the appendix:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">the remote voting form;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">the voting proxy;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: justify">the request for an admission card in the name of the shareholder or on behalf of the shareholder represented
by the registered intermediary.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">A certificate is also issued to any shareholder wishing to attend the meeting
physically and who has not received his admission card by the second business day preceding the Shareholders&rsquo; Meeting, which will
be Monday May 20, 2024 at 0:00 am, Paris time, France.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>B. Participation&rsquo;s terms to the Shareholders&rsquo; Meeting</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shareholders&rsquo; Meeting is composed of all shareholders regardless
of the number of shares they hold.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Each shareholder may be represented at the Shareholders&rsquo; Meeting
by another shareholder, by their spouse or by the partner with whom they have concluded a civil solidarity pact. They may also be represented
by any other natural or legal person of their choice (Article L.22-10-39 of the French <I>Code de commerce</I>).</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In accordance with Article R.22-10-28 of the French <I>Code de commerce</I>,
the right to participate in the Shareholders&rsquo; Meeting is justified by registering the securities in the name of the shareholder
or the intermediary registered on their behalf (in application of the seventh paragraph of Article L.228-1 of the French <I>Code de commerce</I>),
on the second day preceding the Shareholders&rsquo; Meeting, that is Monday May 20, 2024 at midnight, Paris time, either in the registered
(<I>au nominatif</I>) securities accounts kept by the Company (or its agent), or in the bearer (<I>au porteur</I>) securities accounts
kept by the authorized intermediary.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The registration of the securities in the bearer (<I>au porteur</I>) securities
accounts kept by the financial intermediaries is evidenced by a participation certificate issued by the latter (if necessary by electronic
means) under the conditions provided for in Article R.22-10-28 of the French <I>Code de commerce</I> (with reference to Article R.225-61
of the same <I>Code</I>), in the appendix:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the remote voting form;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the voting proxy.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><U>I. Vote by post or proxy</U></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><U>1.1. Postal voting</U></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">Shareholders wishing to vote by post or be represented by giving a proxy
to the Chairman of the Shareholders&rsquo; Meeting or to a proxy may:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><U>For registered shareholders</U>: return the postal or proxy voting form,
which will be sent to them with the invitation, to the following address: UPTEVIA Service Assembl&eacute;es &ndash; 90-110 Esplanade du
G&eacute;n&eacute;ral de Gaulle &ndash; 92931 Paris La D&eacute;fense Cedex.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><U>For bearer (au porteur) shareholders</U>: request this postal or proxy
voting form from the intermediary who manages their securities as of the date of the Shareholders&rsquo; Meeting. Once filled by the shareholder,
this form will be returned to the account-keeping establishment, which will include a participation certificate and send it to UPTEVIA
Service Assembl&eacute;es &ndash; 90-110 Esplanade du G&eacute;n&eacute;ral de Gaulle &ndash; 92931 Paris La D&eacute;fense Cedex. To
be taken into account, the postal voting forms must be received by the Company or the Shareholders&rsquo; Meetings Service of Uptevia,
at the latest on the fourth day preceeding the Shareholders&rsquo; Meeting, <I>i.e.</I> Saturday May 18, 2024. In practice, to ensure
that their voting form will be taken into account, shareholders are advised to arrange for their voting form to be received by the Company
or Uptevia's General Meetings Department by Friday May 17, 2024 at the latest.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In any case, as of the twenty-first day preceding the Shareholders&rsquo;
Meeting, the single remote voting form or voting proxy is available on the Company&rsquo;s website.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><U>1.2. Electronic voting</U></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">Shareholders also have the possibility of transmitting their voting instructions,
of granting a power of attorney to the President of the Shareholders&rsquo; Meeting before the Shareholders&rsquo; Meeting, and of appointing
or removing a proxy by Internet before the Shareholders&rsquo; Meeting on the Votaccess website, in accordance with the conditions described
below:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><U>For registered shareholders (<I>actionnaires au nominatif</I>): </U>holders
of pure or administered registered shares who wish to vote by Internet will access the Votaccess&rsquo; website via the Planetshares site,
the address of which is as follows: https://planetshares.uptevia.pro.fr.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Holders of pure registered shares must connect to the Planetshares site
with their usual access codes.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Holders of administered registered shares will have to connect to the Planetshares
site using their identification number, which is found at the top right of their paper voting form. This identification number will allow
them to have a passcode and to access the Planetshares website. In the event that the shareholder is no longer in possession of their
username and / or password, they may contact the number 0 800 600 700 made available to them.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">After logging in, the registered shareholder must follow the instructions
given on the screen in order to access the Votaccess&rsquo; website and vote, or appoint or dismiss a proxy.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><U>For bearer shareholders (<I>actionnaires au porteur</I>): </U>it is
up to the bearer shareholder to inquire in order to know whether his account-keeping establishment is connected or not to the Votaccess&rsquo;
website and, if necessary, if this access is subject to specific conditions of use.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If the shareholder's account-keeping establishment is connected to the
Votaccess&rsquo; website, the shareholder must identify himself on the Internet portal of his account-keeping establishment with his usual
access codes. He must then click on the icon which appears on the line corresponding to his actions and follow the indications given on
the screen in order to access the Votaccess&rsquo; website and vote, grant a power of attorney to the President of the Shareholders&rsquo;
Meeting or appoint or dismiss a proxy.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If the shareholder's account-keeping establishment is not connected to
the Votaccess&rsquo; website, it is specified that the notification of the appointment and the revocation of a proxy may however be made
electronically in accordance with the provisions of Articles R.225-79 and R.22-10-24 of the French <I>Code de commerce</I>, in the following
ways:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18.7pt"></TD><TD STYLE="width: 35.3pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the shareholder must send an email to Paris_France_CTS_mandats@uptevia.pro.fr. This email must contain
the following information: name of the Company concerned, date of the Shareholders&rsquo; Meeting, last name, first name, address, bank
references of the principal as well as the name, first name and if possible, the address of the agent; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18.7pt"></TD><TD STYLE="width: 35.3pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the shareholder must obligatorily ask their financial intermediary who manages their securities account
to send a written confirmation to the Shareholders&rsquo; Meetings department of UPTEVIA Service Assembl&eacute;es &ndash; 90-110 Esplanade
du G&eacute;n&eacute;ral de Gaulle &ndash; 92931 Paris La D&eacute;fense Cedex.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Only notifications of designation or revocation of mandates may be sent
to the aforementioned email address, any other request or notification relating to another object that cannot be taken into account and/or
processed.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In order for appointments or revocations of proxies expressed by electronic
means to be validly taken into account, confirmations must be received no later than the day before the Shareholders&rsquo; Meeting at
3:00 p.m., Paris time, France. No proxies will be accepted on the day of the Shareholders' Meeting.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Votaccess&rsquo; website will be open from May 3, 2024 at 12:00 a.m.,
Paris time, France.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The possibility of voting online before the Shareholders&rsquo; Meeting
will end the day before the meeting, <I>i.e.</I> Tuesday May 21, 2024 at 3:00 p.m. Paris time, France.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">However, in order to avoid any saturation of the Votaccess website, shareholders
are recommended not to wait until the day before the Shareholders&rsquo; Meeting to vote.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><U>II. Presence at the Shareholders&rsquo; Meeting</U></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">Shareholders wishing to attend the Shareholders&rsquo; Meeting in person
may request an admission card by mail or electronically as follows:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><U>2.1. Admission card request by mail</U></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><U>For registered shareholders: </U>request for the admission card must
be addressed to UPTEVIA Service Assembl&eacute;es &ndash; 90-110 Esplanade du G&eacute;n&eacute;ral de Gaulle &ndash; 92931 Paris La D&eacute;fense
Cedex, or present themselves the day of the Shareholders&rsquo; Meeting at the dedicated counter with an identification document;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><U>For bearer shareholders: </U>request the financial intermediary in charge
of the shares registration to have itself delivered an admission card.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><U>2.2 Admission card request by email</U></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">Shareholders wishing to attend the Shareholders&rsquo; Meeting in person
may also request an admission card by email as follows:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><U>For registered shareholders: </U>the holder of share in pure or administered
registered form, wishing to vote by Internet, will access to the website VOTACCESS via the website Planetshares, which address is the
following: https://planetshares.uptevia.pro.fr.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The holder of shares in pure registered form shall connect to the website
Planetshares by using its usual access codes. The holder of shares in administered registered form shall connect to the website Planetshares
by using his ID number on the upper right of his voting paper form. In case the shareholder is not in possession of his username and/or
password any more, he can contact the number 0 800 600 700 at his disposal or proceed via a contact form. After being logged in, the holder
of shares in registered form shall follow the guidelines on his screen in order to access the website VOTACCESS and vote or designate
or revoke a representative.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><U>For bearer shareholders: </U>it is the responsibility of the bearer
shareholder to assess whether or not the financial intermediary has access to the VOTACCESS secure platform and, if so, whether this access
is subject to any particular conditions of use. Only bearer shareholders whose financial intermediary has subscribed to the VOTACCESS
service will be able to request their admission card online. If the financial intermediary is connected to the website VOTACCESS, the
shareholder shall identify himself on the internet portal of his account holder establishment with his usual access codes. He should then
click on the icon appearing on the corresponding line of his shares and follow the guidelines written on the screen in order to access
to the VOTACCESS website and vote or appoint or revoke a representative.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>C. Request for draft resolutions or items to be included in the agenda
and submission of written questions</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">1. Requests for the inclusion of items or draft resolutions on the agenda
by shareholders who meet the conditions set forth in Article R.225-71 of the French <I>Code de commerce</I> must be sent to the company's
registered office by registered letter with return receipt requested at the following address: GENFIT, Service Financier, Parc Eurasant&eacute;,
885 avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos, France or by email at the following address: investors@genfit.com within 20 calendar
days from the publication of this notice, and must be received by no later than the 25<SUP>th</SUP> calendar days before the Shareholders&rsquo;
Meeting, in accordance with Article R.22-10-22 of the French <I>Code de commerce</I>. Requests must be accompanied by a securities account
registration certificate.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Each request must be accompanied, as the case may be, by the text of the
proposed resolutions, which may be accompanied by a brief explanatory statement. In addition, the Shareholders&rsquo; Meeting's consideration
of draft resolutions and items submitted by shareholders is subject to the authors maintaining the registration of securities in the same
accounts on the second business day preceding the Shareholders&rsquo; Meeting at midnight, Paris time, France.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">2. In accordance with Article R. 225-84 of French <I>Code de commerce</I>,
each shareholder has the possibility to send to the Board of Directors, which should answer during the meeting, the written questions
of his choice.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The questions shall be sent by registered letter with acknowledgement of
receipt at the following address GENFIT, Service Financier, Parc Eurasant&eacute;, 885 avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos
or by email to the following address: investors@genfit.com.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This mailing shall be realised at the latest the fourth business day preceding
the date of the Shareholders&rsquo; Meeting, which will be the Thursday May 16, 2024.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>D. Rights to shareholder information</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">All the documents and information set forth in Article R. 22-10-23 of the
French <I>Code de commerce </I>can be consulted on the Company&rsquo;s website: www.genfit.fr, as of the twenty-first day before the Shareholders&rsquo;
Meeting, being Wednesday May 1, 2024. All the documents referred to in Article R.225-89 et seq. of the French <I>Code de commerce</I>
are available to shareholders at the Company&rsquo;s registered office as of the publication of this notice of meeting or on the fifteenth
day before the Shareholders' Meeting at the latest, depending on the document concerned.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">*****</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Board of Directors&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>hdr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hdr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ R0,@ P$1  (1 0,1 ?_$ ,$   $% 0$!
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M:8=3(HH!#0##0 U]*1H#JK&IR>"M+O3E%B4BJE2,FF#P: 6@$O0'4 AH!BJ
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MK:*SJ:P#D9R_6M*J)<1@DB_97/O&VJP0C:;WTKFNCIUV&2\.PUCMJWUV%3(
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M?PO(U2J_=1W%A897$0\=BH#S3I7.DI*GV_LI3W4#"/#Y!)0/E3^]:4+;7/$
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MJ&0H:5R=[L[%[BX=R-*SVV:ZZ-/%A) 2+5A;AM-%BQ$3NU&E3W9.ZM+BH3(
M( O6W''/S+0,I3<BNWCCS.2]5;R*:8/'LI*'5J.NWO(M_P!-=!1\G('GSCN6
M4I *W%C4Z]@]M9V*3%P'6UL1T-MQ3*%VUK-RVWVJ5W4PCS,<XS)3C6'FY+KO
M24@V0H>TF@!9#"3H*V434I+8U\QLA0/T4'E6SWMRR$BP[NG2@\G-+*(I(/B(
MH+!D>:\WX022?LBD(N\?F8K+:HV2B(E1WM#N\*T^T*J<5IF(\S#X<%$C'R5.
M-E5EQG/B /<>VGE-!S\CS/):;:"6F4;3M%@3[:,Q-5T($N@I5MV]4G6F,5+<
MRCK<@I03M2+'W=U&!E-@SL2\L"9%#B>U2/"L>WNJ>JX+DN-+D_WG$/\ S;"A
MI'-@ZGV$=M&18BX3#QWER#D%*9#"22G[6X=E.5.,*]C)R8CY4RLBQ\.NH%!K
M>/DE/%4MZR5@6W 6)H.!*PS4YPKC2T^8X;E#FFO=>B;"ZF3,5D<(T?G&2VI>
MC:QXD&_<H4\HZQ6Q7Y'F6:*MY/A2.I/LM2ISJTK?(YC;1QF9:#C=K*0X/&GW
M&IQ5](KI.'@JLY!?W-*.K2]5 >RJ+ _)IWFM0HNP-MQ6P 0+ GWT0E3 4\IX
M("CY8-SKUJL1%M7W]<QA6J-+@IE,6L+JVJ2?S2*BQ>NR<G!\4>8;DX:6\F61
MXX,D I"NY*]*%6QFIK$EN0Z)*"A]/4*.MNRW?5)DZKJ;C\OQEK&S77"I.0:#
MS8!U">XU,@VEC4\'./E-YY\,I>1+C;/*4-"ZH_$@>RIV7I,>K00N3NXKC<?C
M<*02F#94@I-EJW?'L/LHA9BE)6Y%?0XHK=8>))5HJQ[ZTE148H[M*I)%)Z6^
MJD>3DNNHZ+(]QH3@Y4Z7J XJWOIF"M]\FZEDCWT C$M3;H)-9[S(UO5/\XK\
M0/6N;&'1+*;N-]31W'6EPDE#+863KW5OQQR<L;/!RB[XB;D]:]#7T82-4POP
M]:,&FXE5\K#'_;(_'4[>@GJ]$4-:YG21*: )MH(Q::01U:*IA*97TH"0A>H]
M](Y7S(QS5?#_ %IY3E48YW*%R1*8^7944J&YT'=<)<Z;>ZO5O%W\6LSAX4Y_
ME\^UQGU:'A.&Y;S;U81SK*8IS$8V(0XD.)4C<6FRVTVC>$J6=;J5:U9<NVO'
MQ]DN:VX--^7F^9M,2*_U$S$[#?\ ,"WDX$!>4F1FF%-0&[A;I5%*2!M"SH#?
MI5\.LVX,6X9^3O=?)S)F_P#0+&.9OU?]2(K^2;8Q,? )0J1#!5YP;;=W% 2N
MRE+*]%&P":-L</'TZY&EV\GEZ].U>?\ -&I1/&"D75YDDI'M_=VJ/ ^+7[K_
M *5_@<_Z[O9J SF<!#CXE;R$SGT!.Y#)/B4+.JU ]E9;Z<.+B]6_'R>1=IW:
MS"O]4?3OER^5L<XX:[ORK"$!V+=(<W-)V!;07X5A2-%(-5P<VO;V;^B/*\;?
MO^9IZI'IUZRO9W+#CG(8/]-SX*DME(4EMQ;8NI"FU^)M=@3W&ES^-VSNUN8K
MQO-[]NS:8V9_EO#.=\4YE-YIPW^^,2RMV7% #CB0X=SK:VCJXV2+@IU%:<?+
MIOK--V/-P<G'O>3CZY:STW]5XO,$NPI$?Y',Q4>8['!);6@':I;=_$+$C<DZ
MBL/(\>\?7UCI\7RYR]/3:-CD'K8V8/\ ]N]_[M5<\]8[-O2_D^;?37U%SG#L
M!DUX_"G(,./-N/3EEP,L*"=J0O8FVOM4*];R?'UY-IFX>!XGE[<6MQKEZ-Z"
M<2F 3>:37VENYH+0PRR;[07=[JEV^%6\6">RN/SN3TTGP=_VWBLSR7_4QXD\
MOB^MG(U\4A-3\KYDA)8>MM\H^7O5JI&H-NVNCMTO#K-[B.7NWGD[729KV/T\
ME^HDQR9_QGC&<=Y9:^1\@ ;[D^9>RW.FE</-IQS'9<O4\??EN>^8>>>@8_\
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MX)F7QCZA82&1N;W?G)TI8:8B'GL1)Q@#"5"1%.J)37PK'M'93PSV5>.BO2I
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C&NB.?8?NJD$-(!.=M*KB$]451K52I,:Z5<14M'2K0?3)_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 footer.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  B SH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBN3U?X
MC^&M&U![":\DGNX_]9%:PM*8_J0,#Z9HN!UE%<L_Q#\-KX:?7X[QIK!)1"YC
MC.]7/8J<$5'I'Q%T76M3AL+6'45FFSM,MHR+P">2>G2CR#I<ZVBL?P]XGTKQ
M1:S3Z7.9!#(8Y49=K(P]1[^M1+XNTIDUM@\N-&)%W^[Z8!/R^O -#T W:*X>
MU^*WAV]EA2"+4V\Y@J-]C;:<G'7TK1E\>:+%'JK_ .E/_9<ZV]RL<!8AV) P
M!U'!H Z>BN"7XO\ AEY'C2/4VD3[RBS8E?J.U=??ZG'8Z%<ZJ8V>.&W:XV="
M0%W8]C0]%<%J[%ZBHK:<7-I#< %1*BN >V1FL!_'.B)*V7N3:I+Y+7PMG-NK
MYQ@R8QUXST]Z;5G82=U<Z2BLG5?$5AI%Q#;2BXGNYU+QVUK"TLC*.K84<#W-
M.M/$.FWVCSZI!,QM[</YP9"KQ%!EE93@@CT-*^EQ^1J45S^D^+K;6;F&&WTS
M68UF7<D]Q821Q8QD'>1CGMZUT%%@"BL?1O$^E:]>ZA::?.9);"7RI@5P,Y(R
M/49!&?:MB@ HHHH **** "BBB@ HKDU^(&G2RSI;:9K=TL$K0O);:=)(F]3@
MC<!BNGM;@75I%<".6,2H'"2H4=<CHRGD'VHZ7#K8EHHHH **H:9J]KJIND@\
MQ);64PS12KM=&Z]/0CD'H:OT %%%% !16/K_ (GTOPTMHVISF,74PACPN>?4
M^@'<UL4 %%5=3OXM*TVXOIHY9(X$+LL*%W('H.]2VTZW5K#<(KJLJ!P'7:P!
M&>0>AH EHHJAI^L6NIW-Y#:^8XM)/)DEVX0OW53WQWQTH OT444 %%8FL^*+
M/1+V"SEMK^ZN9HVE6*RM6F8*" 20O09(I[>);"#03K%\+BPM0<%;N!HY,YP!
ML(SDGH,<T>8>1L45AZ/XKTS6KQ[*$75O>*GF?9[RW>%V3^\ P&1]*DN/$^DV
M_B.UT!KD-J5PI984&=H )^8]N <4 ;%%9.M>(]/T'R$NVF>>X)$-O;PM++)C
MKA5!.!ZTRR\5:-?:/<:JEV([6U)6X,R&-H6'4,I&0?:CS V:*Y_2?&>D:O?)
M90M=07$J&2!+JV>'ST'5DW ;A]*T=9UBTT'2IM2OBXMX=NXHNX\L%''U(H O
MT4@(8 CH>:6@ HHHH **** "BLC7_$=EX=BMGO([F1KF7R88[:$RN[X)P%'/
M:J]EXLMKS[06TS6+5((6F>2[L)(5VKU +#!/M1?J%C?HKDK;XC:'.MO++'J-
MI;7) ANKJRDCA<GIA\8Y]<XK?UC5[/0M)GU.^D*6T"@L5&2<G  '<DD4/35@
MM=$7J*IV.J6FHZ1#JEM)OM9HO.1L<[<9Z>M1:'KNG^(]*CU+3)_-MY,C.,%2
M.H([&BVM@\S1HK-L]=L+VUO;E)O+@LIY()WE^4*R?>.3V]ZQA\1- ($O^GBR
M)P+XV,HMS_P/;C'OTH ZNBN;U#QKI]AJ\NF+9ZG>7,,:R2"RLWF"JPR"2M:V
ME:FFK69N4M;RV&XKY=Y;M"_'?:W..>M %ZBL^TU5+O6=1TU8F5[(1%G)X;>"
M1CZ8J^2%!)( '<T +145Q<PVEK+<W$J101*7>1S@*HY)-8.F^.-%U2_@LXFN
MX7N03;/<VLD27 '/R,P /'-'6P>9T=%<[JGC71])OI;.4W<\L"AKC[+:O,+=
M3R"Y4$+QS5F^\4Z1I^EVNHR77FP7>!;"!&D><D9 15&2:.EP\C9HK)T3Q'I^
MOK.+-IDFMV"SV]Q"T4L1/(W*P!YJ36M>T_0;>.6^D<&5_+ABBC:225O154$D
MT/0-S2HK&TKQ1I6KVMW/#,\/V/\ X^H[J-H7@XS\ZL 0,<YJIIWCG0]3OH+6
M*2YC-R2+66XMI(H[C'_/-F #4=;!YG245CZWXHTGP_+:1:A<A)KN58H8E&YV
M).,X].>M:Y(4$D@ <DGM1TN M%9VC:W9Z]:R75@9'MED:-963:LA7@E?49[U
MH$@ DG '4F@!:*R-&\3:5KUK>75A<;[>TF:&25AM7*@$D$]1@]:HV7CS0;^]
M@MHI;E%N7V6UQ+;2)#.WHCD8)_G1Y =+16#J_B_2M&OOL4QNI[I4\R2*TMGF
M:)/[S[0=H^M3S>)]&AT!-<:^C.G2 %)5!.\DX"@ 9+9XQC-'2X>1KT5BZ-XI
MTW7+F6UMS<0W<2AWMKN!H9 IZ-M8#(]Q5K4]633)M/C>)G-[="V4@XVDJS9/
M_?- &A1110 4444 %%%% !1110 4444 %%9NL:[9:'' UT96DN)/+@A@B:22
M5L9PJCD\<TVSUZUO+J]MQ#=0-9HCRM/"47#+NX)ZX'7TH U**AM+J"^M(;NV
MD$D$R"2-P/O*1D&IJ "BBB@ HHHH **** *VH&==-NC;#,XA<QC_ &L''ZUY
M[\)&B@^'<UW96PNM5,LK7,>\+))*"=JECTXQU]:]+KCM1^&VC7NIS:C:76IZ
M3<SG,S:;=&$2'U(P1^5+9OS'NEY'#>-O$H\0?#K6D.D#3+BRU..&>+S%?,F>
M22H )]^:]'\/2^*7.-;MM*BM1"/+:TE=G+<8R& &,9K/D^&.@OX9N-"62^2&
MYG6XGG$P::1QW)8$?I4^D>!$TC4H+Q?$WB2[$6<07=_YD39!'*[1GK3Z-?UM
M8E]'Z_F>7>%+/4?#NAKXVT</,L5U-%J=F#_K8 _WA[K_ )[YU](U"VU;1/B;
MJ%H^^WN 9(VQC(,;5Z=X=\-V7AK26TVT>:6!I'D)G(8DL<D< #'X5FV'P^T7
M3-/UNQLS<Q6VL9$R!UQ$"",1\<=3US2DKIKRM^7^1:?O7\[_ (O_ #.<^'%W
MXP_X1_0X?[,TW^QO+ \_SCYNSGG;TS4_PY_Y'#QW_P!A%?YO7;Z)I%OH.BVF
MEVKR/!;1B-&E(+$>^ !^E5-%\,66A:EJU]:RW#RZI,)YA*RE589^[@# ^8]<
MU;?O-^OZ?Y$)6C;T_4Y+PA_R5SQM](/_ $&NN\7?\B9K?_7A-_Z :;IOA>RT
MOQ%JFMP2W#7.I;/.1V4HNT8&T  C\2:G\26LU[X7U6UMHS)/-:2QQH#]YBA
M'YUE/^';R_S+C_$OY_Y$NGR)%H%K)(<(EJC,?8*,UY8L.M2?#"<P);#PNQ>8
M1LQ^V?9=Y8C/W-W7'M[UZQ80M'I5K!*F&6!$=3SSM (KGCX T_[*U@NHZHFD
MLQ)TY9P(<$Y*_=WA<]MV*UG\<FOZUN1#2,?ZZ&3<7%S?>.K*;PP(/M*:2IN&
MO<^5Y#MF, +\V_(SZ8IOA_3I=5TCQ=H=U/\ 9M9N+EQ?31KOB!D0;3&,@[=H
MZ'GKFNFU#PK9WE]#?6US=Z;>10^0)K)U4M&.B$,K*0.W'%);^$=/MM*O+%)[
MW?>2>;<7?VAA/(_&&WC&,8' X]JEVU^?YW&M+?+\$8T-QKOA?7M%TR^U.'4[
M#4"UN@%J(9(&5,@C:2"N!@YZ5L^,M;/A_P *WU]&"UQL\NW4#):5OE4 =^3G
M\*;IGA&TT_4TU&>_U'4KR)"D,M_.)/)!Z[0  ">YQFKNJ:';:Q=Z=/=238L)
M_M$<2D!'<# +#&3C.1@BB7O*S_K^OU".CNOZ_K0\UTJ[TWPSK7AF2R-YL>#^
MSM1>:QFA5F8[E<LZ 9\PGOG#5N3>*+_0['Q'IMU,UQJEK.!IQ<#=*LYQ#]=K
M$@_[M=AKFC6OB#1[C3+PR"&8#+1D!U(((*D@X((%4KSPEIM_KNF:Q<M.]WIZ
M;4.X8D]"XQR022,8Y-&^_P#2>OYZ>C\@VV_I_P#!_0Y.;5-<?7)=",VM2IIE
MK!YTVF)"9)IG7)9S)T7T 'KFI+G5?$[67ARVN9Y].O+K4I+625XDWR1;&*L4
M&5#$ 'TR/3BNKU+PS;W^IC4X+V]T^^\ORGGLW53(@.0&#*RG'.#C-(WA>UD&
ME&:[OIGTVX-S')+-O:1R"#O)'3YCP,8H7G_6K#T_K0Y;4-3U;0KGQ+I0U6YN
MU@T8W]M/<!/-B?YE(RJ@$9 /(XK2U75K^#0_"$T5RZR7E]9QW##'[Q77+ _6
MMNX\-V%UK%WJ4_FR/=67V&6(D>68\D],9SR>]9L7@2S0:>LNJ:M<1Z=/'-:Q
MS3J5C*'@8"C([<Y..A%"Z7\OU_X _3S_ "7_  3 FUS6]8UC61;_ -NQ0V-R
MUK;+IL-NR;E RTGF'+$D].!BNYT*XO[K0K*;5+?[/?O$//B_NOWZ?G6?=>$[
M>74KB^L]2U'39;K!N!9RJJRD#&XAE;!QQD8-;=K;K:VL5NKRNL:A0TKEW;'<
ML>2?>A;6$]SS;P2?% MM5_LJ/1S9_P!KW.3=/*),[^?N@C%=18:A=R_$36-/
MDG9K6&RMY(XNRLQ;)'UP*K0^ 8[22Y-EXDUZTCN)WG:*&>(*'<Y.,QFKL_A&
M"6\@O8]5U.WO4MUMI;B&5 ]P@Y'F94@G.>0 >:%HEZ?HD#U;]?UN<F?$>K#P
MZTTNH3Q0MK\UI<74<8>6& ,0H1<')S@="1FGCQ!K.DZ/XCUB*^OM0TVTC1-.
M:]MUC,CM@,Q^168*3C/ //UJWK7A#^S=.T^TTZ#4;K3X]1>]N?(G'VI&(.TQ
ML2"0">>=V.YJUHFDWM_>:A#?1ZHWA^XM?)-MJ\H>1Y">67!)5=O')Z_2DEI;
M^ME_D[>H[ZW_ *W?_ N5=)N?$<6L:>PAUVXBG?;?G4(;=8U7:?G3RSE<'''(
MP?6LN#4/$#?#RY\4MXANOM-H\K1P"./RF5)2NUQMRV0.N1CC\>WTWPP-.G@?
M^VM7N(;<8BMY[@%%&, ':H+8']XFF)X/T^/PC/X;$UU]CG$@9RR^8-[%C@[<
M=3Z4WY?UK_D)=+_UH<[JWB'5-0\3?V7:IJT=K#917$G]EI"97>3.,M(>% '8
M<FNE\)W&KW&D/_;,,T<\<[I&TZ(LDL0QM9@A*@\X./2B]\*VMU<VUW!>7MC>
MP0BW%S:R*'>,?PL&4JPSSR*T=.T\:=9_9Q=75R<EC-<R^8Y)]^@^@ 'M3TUM
M_6O^0M=+_P!:?YGG&M7NE>(?&&M0ZF+IK*RLVT^W,-E-.OG/S(^40@%?E%36
M'BG4/^$.T36C/*O]F70L]7A92-R?<+L",@C*MVZFNZT+0[7P_IOV*U>613(\
MKRS$%Y'8DEF( &>?2JW_  BNG&;6G)F,>L*%NH"PV9"[=RC&02.O)Z"DM%_6
M^_XW:^XIZO\ K;;_ "?WG-ZQKNI7$7B[4;"\>*RTNS:VM]F,-< ;G?\ X#E5
M_.GO=:MJ?BK2-+BUBXL[>?11=3F%4+LP91D%@0I.>N/\:WK;PAIUKX0E\-1R
M7'V.6-XY)2X,K;R2S$XQGGTJQ!X=M+?6+74TDG,]M9?844L-I3(.3QG=P.^/
M:A67]>3_ %8G>W]=U^B9Q%QXKUK2])U2P6XEO+R#6$TZWNC&AEV. P)7A68#
M(&< G&:OV&IZ[I-S<2O::U/I<=G--*=42!625!N&TQGD-R""..*WY/!VE3Q:
MM'/Y\BZG<"YER^#'(  I0@ KC:#WJQI_A_[%,TEQJVIZAF,QA+N92@4]?E55
M!/N<FEK;S_X'^8]+^7_!_P CB-,UCQ5=6>GZK#%KES<W#1R2PO#;K9M$Q&0F
M#O&%/#9R<<]:]/KG++P=!I[11VNK:O%8POOCLEN0(EYSM!"[]O\ L[L5<TC2
M[BQU/5[J:YFDCO+@21122EQ& H!Q_=!.>/856A.IGZOX:U6\\1#6-,UX:?(+
M06VPV:S<;BV<ENYQV[=:QD_M7QIX6@E_T5=7TC5<D'(@N'A8CW(!!]\&NBU7
MPLFIWSW::SK%B\BA)$L[O:C@?[)! /NN*N6>B6FFZ'_9.G&2TA",JR1,#(I/
M5LL#ELG.3GFI6B_K>]RGO_7:QR.EW.I>)OB'%=SV=O:V^AQ212&&<S;YI  4
MW;0. ,D#..._ DU32+#2O'_A9K*V6)KFYNYIG!):1S%U)/)_IVKK-$T:ST#2
MH=.L5811Y)9SEW8\EF/<D\DUDZEX.&IZQ!J<FOZO%-;N[6ZQ&#;#N&"%S$3C
M'J33V:MT%NF7]9GTC1=VOZ@J+-%%Y"2XR[ G.Q1W)..!7GVLZ9=PZ(^JZK#]
MG.LZY:2W5MG(A@#!55_?@9]S78ZWX*AUV_L;V?6=5AFLDVP^1)& &[O@H?G/
MJ,>V*L0^%8#IEYIVI:EJ.K6UVH5UOI$;;C^Z55<'H?P%"TU_K=/\; ]=/ZV:
M_"YG>.@JW7A9TXN!K<"QD==ISO'TV]:/BC_R3O4_K%_Z-2KFF^#++3]1@OY[
M_4M1GME*VWV^X\P0 C!V@ <XXR<FM'Q!H=MXCT2XTJ[DFC@GV[GA(#C#!A@D
M$=1Z4NGSO^*_R&GK_7G_ )E7Q5K,OA_PA>ZG BO-!$/+#=-Q(4$^P)S6'J,F
ML>%ETG4)-<N=16YNXK:[@G2,(WF<;H]J@J0>V3Q6G#X-3$D5]KNLZE:21M')
M:WDT;1NI&.0J \=1SUIUKX,M(;FSEN=1U*_CLF#VL%W,K1Q,!@'A06('0L3B
MJ6]_Z_K^NA/V;&-ITVM>)M-U+6HM=N;!HIYX[2VACC,2",D#S RDL21SR.O%
M5[CQ!K>K:)X>U54U&#3+FW:2^?2HEDF23@#A@3LX8\ GI707'@FREEO/L^H:
ME96UZY>YM;:95BE8_>/*DKGOM(S5NZ\.120VL-CJ.H:7%;1>3&EE*H79V!5E
M8=NN,^]3T^[_ (/WE/?[_P#@$_A^\@O]#M;FVU%]1B=3BY= K/@D<@ 8(Z'@
M=*BT[5-5NM1DM[OP_<65NH;;<O<Q.KX/'RJQ(SUZ5;TC2K71-,AT^S5A#%G!
M=MS,2222>Y))-7:I[DK8X7XC-=)=^%6LHXI+H:LOE)*Y5"VQNI ) _"M26;7
MI?#^L?VU9V%N!:2>5]DG:3/RMG.Y1CM6GJVA6NL7.FSW$DRMI]R+F(1D ,P!
M&&R#QSVQ5V[MDO+.>UD+!)HVC8KU (P<?G4->XUWO^2+3]Y/T_,\BM;R_P!5
M\$^'/"EY90V%CJD$<::C)-O#A<-L50ORNV.,G\ZZ/QIJ5HWB30M"N//:S@87
M]V(;>28X3B)2$4G!;GD=JZ*3PCIDWA.'PY*9GM((U2*4L!*A7[KA@,!AZXJ;
M2?#MOI.H7E^+FZNKN\6-99KEE)VHN !M4 =R?<UHW>5_._\ D9I65O*W^9RG
M@K4H(X_$/A^'SA!:L]S9":%XF,$F3@*X!PK9'2L7PQ'+X.\-:-XFM%=]*N[:
M-=6MU&=AZ"=1[=&]1S7H]YX>M+W7(-7:2>.YBMY+8^6P"R1OV8$'.#R,8YJ;
M2M&M=)T*WT>+?-:P1>2/.PQ9?]K  /Y5*TUZV7X7_-6*>NGK^-OUN>5WT\<_
M@;59%D#:=/XH;[2Z'Y3 902<^AXKV&-(UB5(U41A0%"C@#MCVK$TGP=H^CZ%
M=:+# TNGW,CR/#,0P&[&5' X&.._O5!/A_9I"+7^V]=;3QP+(WO[K;_=R!OV
M^VZA:*WI^27Z!Y^OYW,8G7!\5-?_ +$33F?[';>9]M9P,8.,;0?UKOK'[8;*
M+[>(!=[?WHMR2F?]G/./K7/WO@F"YUN?5K;6=7T^XGB2*06DL:J5087[R$_K
M6UI.G/I=F;=]0O;\[RWG7CJS\]LJH&/PH6UOZW8/>_\ 6R,C1O\ D>/$W^Y:
M?^@-53XASZLGA75H[6PM9;)K)_-FDNBCIP<X0(0>,?Q"M/3+&Y@\6:]=RQ%;
M>Y6V$3Y'S;58-^616Q<VT%Y:RVUS$DL$JE7C<9# ]012:ND4G:5S"MFEO="D
M@\3V&G6UBT<:_P#'X9%D![-N1,<X]<YK'\2?;(/%GA^34DMSHJ7RI:"V)$JS
ME"$,@/!7K]W';-==J.EV>JZ7-IMY")+29-CQ]./;TQ6)8^"+*TO[6[N=2U74
MFM#FVCOK@2)"<8R  ,G'<YJKWE?S_KYD)6C;R'ZE;7(TN_;PG_9?VN>9S=-*
MQ(9\8;E<X?@#G@>E4?"":+=>&-"DLHXQ=V]K(+-;IP9$/W7/'4;AR0/RJU>^
M!K*ZO;NYM]2U73Q>-NNH;*YV1S-C!)!!P2.I!&:GO/!>DW-CI]M;_:-/;3@1
M:3V<NR2($8(!.<@]\@YJ5M]WZC>YE>%C=1^-M=BUE8?[8D@ADWVQ/DF ;@H4
M'Y@V<YSGVKH]6.DV(76]3\J/[ CE)Y/^68;@X]SP/6H=#\-6>A2W-Q'-=7=Y
M=$>?=W<OF2N!T&<  #T %5_$OA*W\3RV;W.HZA;"T?S(TMG0*7[,0R-DCMZ4
MWLK?UN"W=SA_$=I>W/A7Q-XGN8)+0:FMO%';MPZ6R.!N?T9@22.PKI/B,L4?
M@VW-N%$L5Y:FSV]G\Q0-OX9K8LO#"V\5U!>ZOJ>JV]S$8GAOY$=,'KC:BFJE
MCX$TZSN[2:2^U.]BLFW6EM=W.^* C@%1@$D#IDG%-::=+I_=_7XL3[^OX_U^
M!E?$+2+""TBU2.V47T^HV:23DDL5$@P!GH/88JUX]EU"^;3/#.FRK!)J[N)I
MWSA847<XXP<G..#ZUI^(?"B>(V07&KZE;P(R2+!;F(('0Y#?-&3G/OCCI4MW
MX:AO["U@NK^^DNK1S)!?[U2=&.><JH7H<8VX(ZU*6EGW*>]UV,W0;Z_TKQ"/
M"M^ED\:60N+.:SB:)1&K!2C(6;!&1@@U4\=:R#>6OAUY9[2TNE\R]NTB=L0Y
MQY:%0?F;I[#/K70:3X=MM+O9[YKFZO;^91&]U=N&?8.0HV@*HSS@ 5L4WK:X
MEI>QXT^IV'_"&>.K+2&9!Y[/%&D+J! $B4]0,<9XZUUGCY+>/X8-]F"@1K;F
MTV]F#ILVUTUIH-E:#5%P\R:E,TUPDN"N64*0..F%[YK(M/ &F6MQ:L][J=U:
MVCB2VLKFYWP0L/ND+C)QVR3BA>?E^ ;:KS_$@\%8;7?%\DO_ !]?VH5;/7RP
MB[/PQG%<?I@3_A(M-@./[-7Q3?>4/X-PC!3'_ R^*] U3P?9ZCJ<FHPW^HZ;
M=RH(YY+"?R_.4=-P(()'8C!]Z?+X/T:3P[#H:P/%:PL'B>.0B2.0'/F!^N[)
M)S[TEI9]K?U_74;ZKO?^OZZ&;KH5?B7X3:/B9H[M9,=3'Y8(S[;L5;\6?\?W
MAK_L+)_Z*DJQH_A6TTF_DU![N^U"^>/RA<WTPD=$SG:N  !GVH\16-S>7>A/
M;Q&1;?45FE((^5!&XS^9'YTUI;U_43=[^GZ$'C:]O=*T:'5;.9T2RNHI;E%_
MY:0;L.#^!S^%8B^*KR/QM+<RW 'AQFDL4X&!-'&)"^??YU_X#7;WUG#J-A<6
M5PNZ&XC:*0>JL,&N?F\!:1-X/C\,L]U]DC;>)@X\XMN+%BV,9.2#QT-+7^O/
M1_YCT_K[_P#@&#IFLZS:CPUK.I7LALM6FF2>%P-L0DRT';C 4#\:JVOC75+2
MSUN]OI"R7EJU[HZ%1\JES$J>_)C;_@5=SK?ANPUWP^=&N/-BML($:!@KQ[2"
MI4D''3TJOJ/@_2M3;1S,LB+I+JUNL;  @8PK<<KE5...@IV6W3]/\]/Q%=[]
M?U_RU_ YXZWJ7A/4)8=8O9+J-]&%S$9,<W$0Q(HQ_>W*:HV^OZ^FA#0+R\8>
M(GU&&U\]0-PCD E+@=.$WC\*[77O#&G^(Y-/DOO-S8SB>/RV W$?PMD'*G R
M/:B7PQI\WBN#Q&WF_;88#"JAAL(Y^8C&=P!(SGH::>MW_77_ ('H*VFG]/;_
M (/J0^,]0OM*\*7=YI[[)H]FZ7:&,:%@&8 \$@9('K7*P:UJ5G<ZC?V6JZIJ
M6BV&G/<-]MM5CWS@'";C&K$8Y..GZ5K^)O#=R=!U"&R:]OQ?7J7%S#)."Z1A
M@66 G 4C (!/]*K:18:C<:Y"(TUQ-&\F1+V+69ED$N1A5122W7J>!CUJ=7?^
MNG]?,K16_KK_ %\BAI6I^*9/[+ODBUVYEN'C:Z2XAMUM3&WWBFT[EP#D'G..
M>M3VS:WJY\4S#Q#>6J:=>S1VL<*1X&U PW%E)8<].._X=#8>$8M->!(-8U?[
M';L&BLS<CRU Z+D*'*CT+$5<LO#UI8QZLD4DY&ISO/-N8?*SJ%(7C@8'?-.6
MJ?+YV_04=U?R_6YP%TUSXDU'P!J4VH7=M-?12EQ;LJA&$1)9<J<$]#UXK3NY
M[ZZ?QQILFI70AL;2'R&!7</W)9N<?Q$<_IBNBM?"&GVBZ"L<UR1HBLMMN9?G
M#+M._P"7GCTQ5F/PY9)?ZQ=L97;5D1+A&8;0%0I\N!D9!]31-732\_QM;]0A
MHTWY?A>YG^ K%K3PAIDC7MU<":TA8).RE8OD'"X P.>^>E4;!]4\4ZKK4BZU
M=:=;:?>-9V\-JL?+* 2[EU;=DGIP,5H6W@V&VTRWT]=9U@P6\L<D7^D*I4)T
M3*J,KZ@\G YJ2Y\(VTNI7-]::CJ6G27>#<I9S*JS$#&X@J<-CC*X-5)WDV**
MM&QG&;4M<\6ZAHRZM<V-KI<$)=[94$D\D@)W$LI 4 = .M8EUXDUP:0UF-0V
MWUIX@BTUKQ8E_>QL1@LO3.&Y QTKK[SPI;7-['?6U]?V%XL(@>XMI1NE0= ^
M\,&(]2,^]1_\(7I8TRVL$:Y5(+U+\R^8#)-,K;MSL0<Y/7I[8J5Y_P!:_P"7
M^0WY?UI_F8L<6LOXRN?#9\1W_P!D%FMZ)]D7GABQ79NV8VY&?NY[9Q6SX'U6
M\U?PS'/?R"6YBFE@>4*%\S8Y4-@< D 5HKHMLGB.37 \OVJ2U%J4R-FP,6SC
M&<Y/K1H>B6V@:>UG:O*\;323$RD$Y=BQZ <9-"VU_K7_ "!^7]:?YFE1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
